Longitudinal	O
Genome	O
-	O
Wide	O
Association	O
of	O
Cardiovascular	B-DS
Disease	I-DS
Risk	O
Factors	O
in	O
the	O
Bogalusa	O
Heart	O
Study	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
ENS	O
MK	O
TL	O
LP	O
OTR	O
RMS	O
NJS	O
EJT	O
GSB	O
SSM	O
.	O

Performed	O
the	O
experiments	O
:	O
ENS	O
MK	O
TL	O
MS	O
SSM	O
.	O

Analyzed	O
the	O
data	O
:	O
ENS	O
JK	O
OTR	O
RMS	O
SSM	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
WC	O
MK	O
JK	O
TL	O
LP	O
OTR	O
SRS	O
JSV	O
GSB	O
.	O

Wrote	O
the	O
paper	O
:	O
ENS	O
TL	O
OTR	O
NJS	O
SSM	O
.	O

Cardiovascular	B-DS
disease	I-DS
(	O
CVD	B-DS
)	O
is	O
the	O
leading	O
cause	O
of	O
death	O
worldwide	O
.	O

Recent	O
genome	O
-	O
wide	O
association	O
(	O
GWA	O
)	O
studies	O
have	O
pinpointed	O
many	O
loci	O
associated	O
with	O
CVD	B-DS
risk	O
factors	O
in	O
adults	O
.	O

It	O
is	O
unclear	O
,	O
however	O
,	O
if	O
these	O
loci	O
predict	O
trait	O
levels	O
at	O
all	O
ages	O
,	O
if	O
they	O
are	O
associated	O
with	O
how	O
a	O
trait	O
develops	O
over	O
time	O
,	O
or	O
if	O
they	O
could	O
be	O
used	O
to	O
screen	O
individuals	O
who	O
are	O
pre	O
-	O
symptomatic	O
to	O
provide	O
the	O
opportunity	O
for	O
preventive	O
measures	O
before	O
disease	O
onset	O
.	O

We	O
completed	O
a	O
genome	O
-	O
wide	O
association	O
study	O
on	O
participants	O
in	O
the	O
longitudinal	O
Bogalusa	O
Heart	O
Study	O
(	O
BHS	O
)	O
and	O
have	O
characterized	O
the	O
association	O
between	O
genetic	O
factors	O
and	O
the	O
development	O
of	O
CVD	B-DS
risk	O
factors	O
from	O
childhood	O
to	O
adulthood	O
.	O

We	O
report	O
7	O
genome	O
-	O
wide	O
significant	O
associations	O
involving	O
CVD	B-DS
risk	O
factors	O
,	O
two	O
of	O
which	O
have	O
been	O
previously	O
reported	O
.	O

Top	O
regions	O
were	O
tested	O
for	O
replication	O
in	O
the	O
Young	O
Finns	O
Study	O
(	O
YF	O
)	O
and	O
two	O
associations	O
strongly	O
replicated	O
:	O
rs247616	O
in	O
CETP	B-GP
with	O
HDL	O
levels	O
(	O
combined	O
P	O
=	O
9	O
.	O
7	O
×	O
10	O
−	O
24	O
),	O
and	O
rs445925	O
at	O
APOE	B-GP
with	O
LDL	O
levels	O
(	O
combined	O
P	O
=	O
8	O
.	O
7	O
×	O
10	O
−	O
19	O
).	O

We	O
show	O
that	O
SNPs	O
previously	O
identified	O
in	O
adult	O
cross	O
-	O
sectional	O
studies	O
tend	O
to	O
show	O
age	O
-	O
independent	O
effects	O
in	O
the	O
BHS	O
with	O
effect	O
sizes	O
consistent	O
with	O
previous	O
reports	O
.	O

Previously	O
identified	O
variants	O
were	O
associated	O
with	O
adult	O
trait	O
levels	O
above	O
and	O
beyond	O
those	O
seen	O
in	O
childhood	O
;	O
however	O
,	O
variants	O
with	O
time	O
-	O
dependent	O
effects	O
were	O
also	O
promising	O
predictors	O
.	O

This	O
is	O
the	O
first	O
GWA	O
study	O
to	O
evaluate	O
the	O
role	O
of	O
common	O
genetic	O
variants	O
in	O
the	O
development	O
of	O
CVD	B-DS
risk	O
factors	O
in	O
children	O
as	O
they	O
advance	O
through	O
adulthood	O
and	O
highlights	O
the	O
utility	O
of	O
using	O
longitudinal	O
studies	O
to	O
identify	O
genetic	O
predictors	O
of	O
adult	O
traits	O
in	O
children	O
.	O

Author	O
Summary	O

We	O
have	O
studied	O
the	O
association	O
between	O
genetic	O
factors	O
on	O
a	O
whole	O
genome	O
level	O
and	O
cardiovascular	B-DS
disease	I-DS
(	O
CVD	B-DS
)	O
risk	O
factors	O
in	O
a	O
population	O
of	O
individuals	O
studied	O
from	O
childhood	O
through	O
adulthood	O
.	O

The	O
longitudinal	O
study	O
design	O
has	O
enabled	O
the	O
investigation	O
of	O
genetic	O
variation	O
influencing	O
trait	O
values	O
over	O
time	O
.	O

We	O
have	O
identified	O
DNA	O
variants	O
that	O
are	O
associated	O
with	O
CVD	B-DS
trait	O
values	O
consistently	O
over	O
time	O
,	O
and	O
a	O
second	O
set	O
of	O
variants	O
that	O
are	O
associated	O
with	O
CVD	B-DS
trait	O
values	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

We	O
also	O
show	O
that	O
variants	O
previously	O
identified	O
in	O
adult	O
populations	O
have	O
consistent	O
effects	O
within	O
our	O
population	O
and	O
that	O
these	O
effects	O
are	O
usually	O
similar	O
across	O
childhood	O
through	O
adulthood	O
.	O

The	O
discovery	O
of	O
time	O
-	O
dependent	O
variants	O
that	O
influence	O
CVD	B-DS
trait	O
values	O
over	O
time	O
can	O
potentially	O
be	O
used	O
to	O
screen	O
young	O
individuals	O
who	O
are	O
pre	O
-	O
symptomatic	O
and	O
provide	O
the	O
opportunity	O
for	O
preventive	O
measures	O
decades	O
before	O
disease	O
onset	O
.	O

Introduction	O

Cardiovascular	B-DS
disease	I-DS
(	O
CVD	B-DS
)	O
affects	O
over	O
79	O
million	O
people	O
in	O
the	O
United	O
States	O
[	O
1	O
],	O
and	O
is	O
the	O
leading	O
cause	O
of	O
death	O
worldwide	O
[	O
2	O
]–[	O
4	O
].	O

Identifying	O
the	O
genetic	O
determinants	O
of	O
CVD	B-DS
can	O
lead	O
to	O
more	O
effective	O
diagnostics	O
,	O
prognostics	O
,	O
therapeutics	O
,	O
and	O
,	O
ultimately	O
,	O
preventive	O
strategies	O
.	O

The	O
best	O
chance	O
for	O
prevention	O
would	O
be	O
to	O
identify	O
risk	O
at	O
the	O
earliest	O
possible	O
age	O
.	O

Genome	O
-	O
wide	O
association	O
(	O
GWA	O
)	O
leveraging	O
cross	O
-	O
sectional	O
phenotypic	O
data	O
has	O
been	O
a	O
particularly	O
useful	O
approach	O
to	O
identifying	O
loci	O
that	O
influence	O
many	O
of	O
the	O
quantitative	O
risk	O
factors	O
of	O
CVD	B-DS
[	O
5	O
]–[	O
10	O
],	O
however	O
the	O
use	O
of	O
cross	O
sectional	O
data	O
does	O
not	O
provide	O
insight	O
into	O
how	O
such	O
risk	O
factors	O
develop	O
over	O
time	O
.	O

Longitudinal	O
studies	O
,	O
particularly	O
those	O
that	O
begin	O
in	O
childhood	O
,	O
allow	O
for	O
the	O
identification	O
of	O
risk	O
profiles	O
of	O
susceptible	O
individuals	O
before	O
disease	O
onset	O
.	O

The	O
Bogalusa	O
Heart	O
Study	O
(	O
BHS	O
)	O
is	O
a	O
longitudinal	O
study	O
focused	O
on	O
the	O
early	O
natural	O
history	O
of	O
CVD	B-DS
.	O

The	O
BHS	O
began	O
in	O
1973	O
and	O
includes	O
up	O
to	O
9	O
phenotypic	O
screenings	O
in	O
childhood	O
(	O
4	O
–	O
17	O
years	O
of	O
age	O
)	O
and	O
up	O
to	O
10	O
adult	O
(	O
18	O
–	O
48	O
years	O
of	O
age	O
)	O
cross	O
-	O
sectional	O
screenings	O
.	O

We	O
have	O
conducted	O
a	O
longitudinal	O
genome	O
-	O
wide	O
association	O
study	O
on	O
a	O
subset	O
of	O
the	O
total	O
sample	O
of	O
unrelated	O
individuals	O
with	O
a	O
large	O
number	O
of	O
measurements	O
(	O
mean	O
number	O
of	O
measurements	O
=	O
8	O
,	O
range	O
=	O
4	O
–	O
13	O
)	O
and	O
are	O
of	O
European	O
Ancestry	O
(	O
N	O
=	O
525	O
).	O

Results	O

Longitudinal	O
GWA	O

We	O
conducted	O
a	O
genome	O
-	O
wide	O
association	O
study	O
of	O
longitudinal	O
measures	O
of	O
12	O
traits	O
measured	O
from	O
childhood	O
through	O
adulthood	O
on	O
participants	O
of	O
the	O
BHS	O
of	O
European	O
ancestry	O
:	O
anthropomorphic	O
(	O
height	O
,	O
weight	O
,	O
and	O
waist	O
circumference	O
),	O
blood	O
pressure	O
(	O
BP	O
)	O
(	O
diastolic	O
and	O
systolic	O
BP	O
),	O
heart	O
rate	O
,	O
blood	O
lipids	O
(	O
low	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
),	O
high	O
density	O
lipoprotein	O
cholesterol	O
(	O
HDL	O
),	O
total	O
cholesterol	O
(	O
TC	O
),	O
and	O
triglycerides	O
),	O
and	O
metabolic	O
traits	O
(	O
glucose	O
and	O
insulin	B-GP
).	O

Genotyping	O
was	O
performed	O
on	O
the	O
Illumina	O
Human610	O
and	O
HumanCVD	O
BeadChips	O
[	O
11	O
]	O
for	O
a	O
total	O
of	O
545	O
,	O
821	O
SNPs	O
passing	O
QC	O
and	O
allele	O
frequency	O
filters	O
(	O
see	O
Materials	O
and	O
Methods	O
).	O

Imputation	O
was	O
performed	O
using	O
the	O
CEU	O
HapMap	O
2	O
as	O
a	O
reference	O
population	O
with	O
the	O
computer	O
program	O
MACH	O
v	O
.	O
1	O
.	O
0	O
.	O
16	O
(	O
http	O
://	O
www	O
.	O
sph	O
.	O
umich	O
.	O
edu	O
/	O
csg	O
/	O
yli	O
/	O
mach	O
/)	O
[	O
12	O
],	O
providing	O
genotype	O
estimates	O
for	O
an	O
additional	O
1	O
,	O
622	O
,	O
114	O
SNPs	O
.	O

For	O
each	O
SNP	O
,	O
we	O
tested	O
whether	O
it	O
had	O
an	O
average	O
linear	O
effect	O
over	O
time	O
(	O
SNP	O
effect	O
),	O
and	O
whether	O
it	O
entered	O
into	O
a	O
time	O
-	O
dependent	O
effect	O
(	O
SNPxAGE	O
interaction	O
effect	O
),	O
such	O
that	O
the	O
genotype	O
is	O
associated	O
with	O
variation	O
in	O
the	O
linear	O
trajectory	O
of	O
the	O
trait	O
from	O
childhood	O
through	O
adulthood	O
.	O

Both	O
SNP	O
and	O
SNPxAGE	O
effects	O
were	O
calculated	O
using	O
linear	O
mixed	O
models	O
as	O
implemented	O
in	O
the	O
R	O
nlme	O
package	O
[	O
13	O
],	O
adjusting	O
for	O
age	O
and	O
gender	O
.	O

Table	O
1	O
lists	O
all	O
regions	O
showing	O
SNP	O
effect	O
associations	O
(	O
P	O
<	O
10	O
−	O
6	O
)	O
and	O
Table	O
2	O
lists	O
all	O
regions	O
showing	O
association	O
(	O
P	O
<	O
10	O
−	O
6	O
)	O
with	O
SNPxAGE	O
effects	O
.	O

We	O
analyzed	O
the	O
regions	O
surrounding	O
the	O
top	O
associations	O
for	O
consistency	O
with	O
recombination	O
hotspots	O
and	O
LD	O
relationships	O
(	O
Figure	O
S1	O
)	O
and	O
provide	O
Manhattan	O
plots	O
of	O
each	O
trait	O
association	O
(	O
Figure	O
S2	O
).	O

From	O
both	O
sets	O
of	O
analyses	O
,	O
there	O
were	O
5	O
novel	O
associations	O
with	O
a	O
P	O
-	O
value	O
less	O
than	O
5	O
×	O
10	O
−	O
8	O
and	O
6	O
novel	O
regions	O
where	O
there	O
were	O
at	O
least	O
10	O
genotyped	O
or	O
imputed	O
SNPs	O
with	O
P	O
<	O
10	O
−	O
5	O
.	O

The	O
most	O
significant	O
association	O
(	O
rs7890572	O
,	O
P	O
=	O
3	O
.	O
8	O
×	O
10	O
−	O
10	O
)	O
was	O
observed	O
with	O
a	O
linear	O
triglyceride	O
trajectory	O
effect	O
(	O
i	O
.	O
e	O
.,	O
SNPxAGE	O
effect	O
)	O
on	O
the	O
X	O
chromosome	O
within	O
the	O
IL1RAPL1	B-GP
gene	O
and	O
near	O
the	O
gene	O
encoding	O
glycerol	B-GP
kinase	I-GP
(	O
GK	B-GP
),	O
in	O
which	O
mutations	O
have	O
been	O
implicated	O
in	O
pseudo	O
-	O
hypertriglyceridemia	B-DS
,	O
caused	O
by	O
high	O
levels	O
of	O
glycerol	O
creating	O
measurement	O
artifacts	O
in	O
the	O
triglyceride	O
assay	O
[	O
14	O
].	O

A	O
novel	O
association	O
of	O
potential	O
biological	O
interest	O
involved	O
a	O
SNP	O
effect	O
on	O
insulin	B-GP
levels	O
with	O
variation	O
in	O
the	O
CHN2	B-GP
locus	O
(	O
rs3793275	O
,	O
P	O
=	O
5	O
.	O
8	O
×	O
10	O
−	O
9	O
),	O
a	O
beta	B-GP
-	I-GP
chimerin	I-GP
that	O
has	O
recently	O
been	O
described	O
as	O
part	O
of	O
a	O
fusion	O
gene	O
also	O
containing	O
the	O
insulin	B-GP
receptor	I-GP
that	O
was	O
shown	O
to	O
be	O
responsible	O
for	O
severe	O
insulin	B-GP
deficiency	O
[	O
15	O
].	O

This	O
SNP	O
is	O
also	O
associated	O
with	O
glucose	O
trajectories	O
in	O
our	O
dataset	O
(	O
SNPxAGE	O
;	O
P	O
=	O
1	O
.	O
5	O
×	O
10	O
−	O
7	O
).	O

In	O
the	O
7q11	O
region	O
,	O
25	O
SNPs	O
are	O
associated	O
(	O
P	O
<	O
10	O
−	O
5	O
)	O
with	O
diastolic	O
BP	O
(	O
SNP	O
effect	O
;	O
peak	O
SNP	O
rs709595	O
,	O
P	O
=	O
7	O
.	O
0	O
×	O
10	O
−	O
7	O
).	O

The	O
calcitonin	B-GP
gene	I-GP
-	I-GP
related	I-GP
peptide	I-GP
receptor	I-GP
(	O
CRCP	B-GP
)	O
is	O
approximately	O
200	O
kb	O
from	O
the	O
top	O
SNP	O
,	O
but	O
contains	O
SNPs	O
that	O
are	O
in	O
LD	O
with	O
the	O
top	O
SNP	O
(	O
see	O
Figure	O
S1	O
).	O

The	O
calcitonin	B-GP
gene	I-GP
-	I-GP
related	I-GP
peptide	I-GP
is	O
a	O
vasodilator	O
[	O
16	O
]	O
and	O
its	O
receptor	O
CRCP	B-GP
has	O
been	O
previously	O
implicated	O
in	O
hypertension	B-DS
in	O
a	O
small	O
candidate	O
gene	O
association	O
study	O
of	O
hypertension	B-DS
in	O
Japanese	O
individuals	O
[	O
17	O
].	O

Top	O
SNP	O
effect	O
GWA	O
hits	O
for	O
12	O
phenotypes	O
.	O

Trait	O

Cytoband	O

Gene	O
(	O
s	O
)	O

Top	O
SNP	O
,	O
Alleles	O

#	O
SNPs	O
@	O
P	O
<	O
10	O
−	O
5	O

Risk	O
AF	O

Beta	O
(	O
SE	O
)	O

P	O

diastolic	O
BP	O

5p13	O
.	O
3	O

CDH9	O
/	O
CDH6	O

rs7704530	O
G	O
/	O
A	O

2	O
/	O
3	O

0	O
.	O
26	O

8	O
.	O
44	O
(	O
1	O
.	O
57	O
)	O

1	O
.	O
1	O
×	O
10	O
−	O
7	O

diastolic	O
BP	O

7q11	O
.	O
21	O

TPST1	O

rs709595	O
C	O
/	O
G	O

8	O
/	O
17	O

0	O
.	O
39	O

7	O
.	O
18	O
(	O
1	O
.	O
43	O
)	O

7	O
.	O
0	O
×	O
10	O
−	O
7	O

glucose	O

2q24	O
.	O
3	O

G6PC2	B-GP
,	O
ABCB11	O

rs853773	O
A	O
/	O
G	O

4	O
/	O
1	O

0	O
.	O
53	O

−	O
8	O
.	O
72	O
(	O
1	O
.	O
73	O
)	O

7	O
.	O
0	O
×	O
10	O
−	O
7	O

glucose	O

6q22	O
.	O
31	O

NKAIN2	O
/	O
RNF217	O

rs781718	O
*	O
G	O
/	O
A	O

1	O
/	O
4	O

0	O
.	O
89	O

−	O
3	O
.	O
46	O
(	O
0	O
.	O
69	O
)	O

8	O
.	O
4	O
×	O
10	O
−	O
7	O

HDL	O
-	O
cholesterol	O

16q12	O
.	O
2	O

HERPUD1	O
/	O
CETP	B-GP

rs247616	O
*	O
T	O
/	O
C	O

4	O
/	O
2	O

0	O
.	O
33	O

3	O
.	O
77	O
(	O
0	O
.	O
75	O
)	O

6	O
.	O
6	O
×	O
10	O
−	O
7	O

insulin	B-GP

7p14	O
.	O
3	O

CHN2	B-GP

rs3793275	O
*	O
A	O
/	O
T	O

1	O
/	O
3	O

0	O
.	O
94	O

−	O
4	O
.	O
63	O
(	O
0	O
.	O
78	O
)	O

5	O
.	O
8	O
×	O
10	O
−	O
9	O

insulin	B-GP

20p13	O

RNF24	O
/	O
SMOX	O

rs6052399	O
*	O
T	O
/	O
C	O

0	O
/	O
1	O

0	O
.	O
93	O

−	O
4	O
.	O
55	O
(	O
0	O
.	O
84	O
)	O

9	O
.	O
8	O
×	O
10	O
−	O
8	O

insulin	B-GP

6q14	O
.	O
1	O

BCKDHB	O
/	O
FAM46A	O

rs16892328	O
*	O
C	O
/	O
T	O

0	O
/	O
1	O

0	O
.	O
94	O

−	O
4	O
.	O
93	O
(	O
0	O
.	O
92	O
)	O

1	O
.	O
3	O
×	O
10	O
−	O
7	O

insulin	B-GP

18p11	O
.	O
31	O

MRLC2	O
/	O
TGIF1	O

rs1613695	O
*	O
G	O
/	O
A	O

0	O
/	O
1	O

0	O
.	O
95	O

−	O
5	O
.	O
68	O
(	O
1	O
.	O
07	O
)	O

1	O
.	O
7	O
×	O
10	O
−	O
7	O

insulin	B-GP

14q13	O
.	O
3	O

TTC6	O
/	O
SSTR1	O

rs10498337	O
T	O
/	O
G	O

1	O
/	O
0	O

0	O
.	O
81	O

−	O
9	O
.	O
3	O
(	O
1	O
.	O
87	O
)	O

8	O
.	O
9	O
×	O
10	O
−	O
7	O

LDL	O
-	O
cholesterol	O

21q22	O
.	O
11	O

MRPS6	B-GP
/	O
KCNE2	B-GP

rs8131349	O
*	O
A	O
/	O
G	O

0	O
/	O
1	O

0	O
.	O
06	O

17	O
.	O
6	O
(	O
3	O
.	O
05	O
)	O

1	O
.	O
4	O
×	O
10	O
−	O
8	O

LDL	O
-	O
cholesterol	O

19q13	O
.	O
33	O

APOE	B-GP
/	O
APOC1	O

rs7412	O
T	O
/	O
C	O

1	O
/	O
1	O

0	O
.	O
07	O

−	O
69	O
.	O
74	O
(	O
12	O
.	O
15	O
)	O

1	O
.	O
6	O
×	O
10	O
−	O
8	O

LDL	O
-	O
cholesterol	O

6q22	O
.	O
31	O

C6orf170	B-GP
/	O
GJA1	B-GP

rs7738656	O
G	O
/	O
A	O

1	O
/	O
0	O

0	O
.	O
84	O

−	O
42	O
.	O
39	O
(	O
8	O
.	O
11	O
)	O

2	O
.	O
5	O
×	O
10	O
−	O
7	O

LDL	O
-	O
cholesterol	O

5q33	O
.	O
2	O

KIF4B	O
/	O
SGCD	O

rs10044666	O
*	O
G	O
/	O
T	O

1	O
/	O
3	O

0	O
.	O
72	O

−	O
8	O
.	O
57	O
(	O
1	O
.	O
68	O
)	O

4	O
.	O
7	O
×	O
10	O
−	O
7	O

systolic	O
BP	O

11q24	O
.	O
1	O

ASAM	O
/	O
GRAMD1B	O

rs11822822	O
G	O
/	O
A	O

2	O
/	O
4	O

0	O
.	O
24	O

10	O
.	O
74	O
(	O
2	O
.	O
12	O
)	O

5	O
.	O
6	O
×	O
10	O
−	O
7	O

systolic	O
BP	O

15q22	O
.	O
1	O

RORA	O
/	O
VPS13C	O

rs726914	O
G	O
/	O
A	O

2	O
/	O
0	O

0	O
.	O
62	O

9	O
.	O
21	O
(	O
1	O
.	O
83	O
)	O

7	O
.	O
1	O
×	O
10	O
−	O
7	O

total	O
cholesterol	O

21q22	O
.	O
11	O

MRPS6	B-GP
/	O
KCNE2	B-GP

rs8131349	O
*	O
A	O
/	O
G	O

2	O
/	O
2	O

0	O
.	O
06	O

18	O
.	O
4	O
(	O
3	O
.	O
32	O
)	O

4	O
.	O
6	O
×	O
10	O
−	O
8	O

total	O
cholesterol	O

4p16	O
.	O
1	O

ABLIM2	O

rs6829649	O
T	O
/	O
G	O

1	O
/	O
2	O

0	O
.	O
87	O

−	O
50	O
.	O
96	O
(	O
9	O
.	O
42	O
)	O

9	O
.	O
6	O
×	O
10	O
−	O
8	O

total	O
cholesterol	O

6q22	O
.	O
31	O

C6orf170	B-GP
/	O
GJA1	B-GP

rs7738656	O
G	O
/	O
A	O

1	O
/	O
1	O

0	O
.	O
84	O

−	O
46	O
.	O
21	O
(	O
8	O
.	O
79	O
)	O

2	O
.	O
1	O
×	O
10	O
−	O
7	O

total	O
cholesterol	O

8q24	O
.	O
22	O

ST3GAL1	O
/	O
ZFAT	B-GP

rs4897695	O
*	O
C	O
/	O
G	O

1	O
/	O
6	O

0	O
.	O
91	O

13	O
.	O
66	O
(	O
2	O
.	O
62	O
)	O

2	O
.	O
7	O
×	O
10	O
−	O
7	O

waist	O
circumference	O

8q24	O
.	O
13	O

MTSS1	O
/	O
ZNF572	O

rs891541	O
*	O
A	O
/	O
G	O

4	O
/	O
7	O

0	O
.	O
29	O

4	O
.	O
55	O
(	O
0	O
.	O
91	O
)	O

7	O
.	O
7	O
×	O
10	O
−	O
7	O

A	O
list	O
of	O
all	O
SNP	O
effect	O
P	O
-	O
values	O
less	O
than	O
10	O
−	O
6	O
in	O
the	O
BHS	O
.	O

SNP	O
names	O
marked	O
with	O
an	O
“*”	O
are	O
imputed	O
,	O
while	O
those	O
that	O
are	O
unmarked	O
are	O
directly	O
genotyped	O
.	O

SNP	O
alleles	O
are	O
reported	O
as	O
risk	O
/	O
nonrisk	O
and	O
are	O
in	O
genome	O
forward	O
orientation	O
(	O
build	O
36	O
.	O
3	O
).	O

The	O
number	O
of	O
SNPs	O
@	O
P	O
<	O
10	O
−	O
5	O
corresponds	O
to	O
the	O
number	O
of	O
genotyped	O
/	O
imputed	O
SNPs	O
with	O
P	O
<	O
10	O
−	O
5	O
within	O
200kb	O
up	O
and	O
downstream	O
of	O
the	O
top	O
SNP	O
.	O

Associations	O
at	O
P	O
<	O
5	O
×	O
10	O
−	O
8	O
are	O
indicated	O
in	O
bold	O
.	O

Top	O
SNPxAGE	O
effect	O
GWA	O
hits	O
for	O
12	O
phenotypes	O
.	O

Trait	O

Cytoband	O

Gene	O
(	O
s	O
)	O

Top	O
SNP	O
,	O
Alleles	O

#	O
SNPs	O
@	O
P	O
<	O
10	O
−	O
5	O

Risk	O
AF	O

Beta	O
(	O
SE	O
)	O

P	O

distolic	O
BP	O

14q24	O
.	O
3	O

ESRRB	B-GP
/	O
VASH1	B-GP

rs17104804	O
G	O
/	O
A	O

1	O
/	O
2	O

0	O
.	O
92	O

−	O
0	O
.	O
76	O
(	O
0	O
.	O
15	O
)	O

5	O
.	O
9	O
×	O
10	O
−	O
7	O

glucose	O

16q21	O

CDH5	O
/	O
TK2	O

rs4783595	O
T	O
/	O
C	O

2	O
/	O
1	O

0	O
.	O
87	O

−	O
1	O
.	O
67	O
(	O
0	O
.	O
31	O
)	O

9	O
.	O
5	O
×	O
10	O
−	O
8	O

glucose	O

7p14	O
.	O
3	O

CHN2	B-GP

rs3793275	O
*	O
A	O
/	O
T	O

1	O
/	O
3	O

0	O
.	O
94	O

−	O
0	O
.	O
61	O
(	O
0	O
.	O
12	O
)	O

1	O
.	O
5	O
×	O
10	O
−	O
7	O

glucose	O

Xp22	O
.	O
2	O

ATXN3L	O
/	O
EGFL6	O

rs5979903	O
T	O
/	O
C	O

1	O
/	O
0	O

0	O
.	O
06	O

1	O
.	O
88	O
(	O
0	O
.	O
36	O
)	O

1	O
.	O
9	O
×	O
10	O
−	O
7	O

glucose	O

11q13	O
.	O
5	O

WNT11	O
/	O
PRKRIR	O

rs12807555	O
*	O
G	O
/	O
T	O

0	O
/	O
1	O

0	O
.	O
90	O

−	O
0	O
.	O
47	O
(	O
0	O
.	O
09	O
)	O

2	O
.	O
7	O
×	O
10	O
−	O
7	O

glucose	O

17q25	O
.	O
1	O

PRPSAP1	O
/	O
SPHK1	O

rs9909931	O
G	O
/	O
A	O

2	O
/	O
3	O

0	O
.	O
19	O

1	O
.	O
36	O
(	O
0	O
.	O
27	O
)	O

4	O
.	O
3	O
×	O
10	O
−	O
7	O

glucose	O

1q32	O
.	O
1	O

PLXNA2	O
/	O
LOC642587	O

rs12069004	O
*	O
C	O
/	O
T	O

0	O
/	O
1	O

0	O
.	O
91	O

−	O
0	O
.	O
54	O
(	O
0	O
.	O
11	O
)	O

5	O
.	O
8	O
×	O
10	O
−	O
7	O

glucose	O

8q24	O
.	O
22	O

ZFAT	B-GP
/	O
KHDRBS3	O

rs12548494	O
*	O
C	O
/	O
G	O

0	O
/	O
1	O

0	O
.	O
93	O

−	O
0	O
.	O
6	O
(	O
0	O
.	O
12	O
)	O

7	O
.	O
1	O
×	O
10	O
−	O
7	O

glucose	O

7p21	O
.	O
1	O

AHR	O
/	O
SNX13	O

rs10260737	O
G	O
/	O
A	O

2	O
/	O
12	O

0	O
.	O
89	O

−	O
1	O
.	O
77	O
(	O
0	O
.	O
36	O
)	O

7	O
.	O
3	O
×	O
10	O
−	O
7	O

glucose	O

8q23	O
.	O
2	O

KCNV1	O
/	O
CSMD3	O

rs3019325	O
*	O
G	O
/	O
C	O

0	O
/	O
6	O

0	O
.	O
70	O

−	O
0	O
.	O
31	O
(	O
0	O
.	O
06	O
)	O

7	O
.	O
5	O
×	O
10	O
−	O
7	O

heart	O
rate	O

3q24	O

RASA2	O
/	O
RNF7	O

rs6440031	O
G	O
/	O
A	O

1	O
/	O
0	O

0	O
.	O
90	O

1	O
.	O
33	O
(	O
0	O
.	O
25	O
)	O

1	O
.	O
8	O
×	O
10	O
−	O
7	O

heart	O
rate	O

12q21	O
.	O
2	O

NAV3	O
/	O
SYT1	O

rs1449460	O
G	O
/	O
A	O

2	O
/	O
6	O

0	O
.	O
08	O

−	O
1	O
.	O
36	O
(	O
0	O
.	O
27	O
)	O

7	O
.	O
4	O
×	O
10	O
−	O
7	O

height	O

11q23	O
.	O
3	O

CADM1	B-GP
/	O
BUD13	B-GP

rs1144036	O
C	O
/	O
T	O

1	O
/	O
0	O

0	O
.	O
16	O

1	O
.	O
17	O
(	O
0	O
.	O
23	O
)	O

2	O
.	O
4	O
×	O
10	O
−	O
7	O

height	O

19q13	O
.	O
32	O

PSG3	O

rs8103264	O
*	O
C	O
/	O
G	O

2	O
/	O
10	O

0	O
.	O
93	O

−	O
0	O
.	O
38	O
(	O
0	O
.	O
08	O
)	O

5	O
.	O
6	O
×	O
10	O
−	O
7	O

insulin	B-GP

12p11	O
.	O
23	O

TM7SF3	O

rs1552257	O
*	O
C	O
/	O
T	O

4	O
/	O
10	O

0	O
.	O
20	O

0	O
.	O
18	O
(	O
0	O
.	O
04	O
)	O

7	O
.	O
5	O
×	O
10	O
−	O
7	O

LDL	O

17q22	O

AKAP1	B-GP
/	O
MSI2	B-GP

rs8073909	O
T	O
/	O
C	O

1	O
/	O
0	O

0	O
.	O
64	O

−	O
1	O
.	O
41	O
(	O
0	O
.	O
27	O
)	O

1	O
.	O
4	O
×	O
10	O
−	O
7	O

LDL	O

10p13	O

FRMD4A	O

rs11258628	O
*	O
A	O
/	O
T	O

0	O
/	O
1	O

0	O
.	O
92	O

−	O
0	O
.	O
69	O
(	O
0	O
.	O
14	O
)	O

4	O
.	O
1	O
×	O
10	O
−	O
7	O

systolic	O
BP	O

19p13	O
.	O
3	O

RFX2	O

rs1046391	O
*	O
G	O
/	O
T	O

0	O
/	O
1	O

0	O
.	O
86	O

0	O
.	O
21	O
(	O
0	O
.	O
04	O
)	O

4	O
.	O
1	O
×	O
10	O
−	O
7	O

systolic	O
BP	O

14q24	O
.	O
3	O

ESRRB	B-GP
/	O
VASH1	B-GP

rs17104804	O
G	O
/	O
A	O

3	O
/	O
5	O

0	O
.	O
92	O

−	O
0	O
.	O
91	O
(	O
0	O
.	O
19	O
)	O

9	O
.	O
3	O
×	O
10	O
−	O
7	O

total	O
cholesterol	O

17q22	O

AKAP1	B-GP
/	O
MSI2	B-GP

rs8073909	O
T	O
/	O
C	O

1	O
/	O
4	O

0	O
.	O
64	O

−	O
1	O
.	O
68	O
(	O
0	O
.	O
31	O
)	O

6	O
.	O
9	O
×	O
10	O
−	O
8	O

triglycerides	O

Xp21	O
.	O
2	O

IL1RAPL1	B-GP

rs7890572	O
G	O
/	O
A	O

5	O
/	O
0	O

0	O
.	O
07	O

9	O
.	O
75	O
(	O
1	O
.	O
55	O
)	O

3	O
.	O
8	O
×	O
10	O
−	O
10	O

triglycerides	O

11q23	O
.	O
3	O

CADM1	B-GP
/	O
BUD13	B-GP

rs12280753	O
*	O
T	O
/	O
C	O

7	O
/	O
11	O

0	O
.	O
07	O

2	O
.	O
64	O
(	O
0	O
.	O
47	O
)	O

1	O
.	O
8	O
×	O
10	O
−	O
8	O

triglycerides	O

9q21	O
.	O
2	O

PSAT1	O
/	O
CHCHD9	O

rs13290397	O
*	O
C	O
/	O
G	O

1	O
/	O
3	O

0	O
.	O
89	O

−	O
1	O
.	O
98	O
(	O
0	O
.	O
38	O
)	O

2	O
.	O
4	O
×	O
10	O
−	O
7	O

triglycerides	O

2p16	O
.	O
3	O

FSHR	O
/	O
NRXN1	O

rs6726786	O
*	O
G	O
/	O
T	O

1	O
/	O
3	O

0	O
.	O
89	O

−	O
2	O
.	O
09	O
(	O
0	O
.	O
41	O
)	O

2	O
.	O
9	O
×	O
10	O
−	O
7	O

triglycerides	O

3q22	O
.	O
3	O

IL20RB	O
/	O
SOX14	O

rs12330441	O
T	O
/	O
G	O

2	O
/	O
4	O

0	O
.	O
93	O

−	O
9	O
.	O
54	O
(	O
1	O
.	O
86	O
)	O

3	O
.	O
0	O
×	O
10	O
−	O
7	O

waist	O
circumference	O

20q13	O
.	O
32	O

APCDD1L	O
/	O
STX16	O

rs127430	O
*	O
G	O
/	O
A	O

2	O
/	O
13	O

0	O
.	O
86	O

−	O
0	O
.	O
33	O
(	O
0	O
.	O
06	O
)	O

3	O
.	O
3	O
×	O
10	O
−	O
8	O

waist	O
circumference	O

11q24	O
.	O
1	O

SORL1	O
/	O
BLID	O

rs7121446	O
G	O
/	O
A	O

1	O
/	O
7	O

0	O
.	O
78	O

−	O
1	O
.	O
09	O
(	O
0	O
.	O
21	O
)	O

3	O
.	O
6	O
×	O
10	O
−	O
7	O

waist	O
circumference	O

17p13	O
.	O
2	O

SHPK	O

rs7210277	O
*	O
C	O
/	O
T	O

0	O
/	O
1	O

0	O
.	O
91	O

−	O
0	O
.	O
39	O
(	O
0	O
.	O
08	O
)	O

7	O
.	O
0	O
×	O
10	O
−	O
7	O

waist	O
circumference	O

10q24	O
.	O
2	O

CNNM1	O

rs17568778	O
C	O
/	O
A	O

1	O
/	O
0	O

0	O
.	O
92	O

−	O
1	O
.	O
55	O
(	O
0	O
.	O
31	O
)	O

8	O
.	O
2	O
×	O
10	O
−	O
7	O

weight	O

4q35	O
.	O
1	O

ODZ3	O

rs6552560	O
T	O
/	O
C	O

3	O
/	O
7	O

0	O
.	O
23	O

1	O
.	O
35	O
(	O
0	O
.	O
25	O
)	O

8	O
.	O
5	O
×	O
10	O
−	O
8	O

A	O
list	O
of	O
all	O
SNPxAGE	O
effect	O
P	O
-	O
values	O
less	O
than	O
10	O
−	O
6	O
in	O
the	O
BHS	O
.	O

Associations	O
at	O
P	O
<	O
5	O
×	O
10	O
−	O
8	O
are	O
indicated	O
in	O
bold	O
.	O

SNP	O
names	O
marked	O
with	O
an	O
“*”	O
are	O
imputed	O
,	O
while	O
those	O
that	O
are	O
unmarked	O
are	O
not	O
.	O

SNP	O
alleles	O
are	O
reported	O
as	O
risk	O
/	O
nonrisk	O
and	O
are	O
in	O
genome	O
forward	O
orientaiton	O
(	O
build	O
36	O
.	O
3	O
).	O

The	O
number	O
of	O
SNPs	O
at	O
P	O
<	O
10	O
−	O
5	O
corresponds	O
to	O
the	O
number	O
of	O
genotyped	O
/	O
imputed	O
SNPs	O
with	O
P	O
<	O
10	O
−	O
5	O
within	O
200kb	O
up	O
and	O
downstream	O
of	O
the	O
top	O
SNP	O
.	O

In	O
addition	O
to	O
novel	O
associations	O
,	O
there	O
were	O
three	O
regions	O
showing	O
SNP	O
associations	O
that	O
have	O
been	O
previously	O
identified	O
in	O
GWA	O
studies	O
:	O
rs853773	O
[	O
18	O
]	O
near	O
G6PC2	B-GP
was	O
associated	O
with	O
a	O
glucose	O
SNP	O
effect	O
(	O
P	O
=	O
7	O
.	O
0	O
×	O
10	O
−	O
7	O
),	O
rs247616	O
[	O
5	O
]	O
near	O
CETP	B-GP
was	O
associated	O
with	O
an	O
HDL	O
SNP	O
effect	O
(	O
P	O
=	O
6	O
.	O
6	O
×	O
10	O
−	O
7	O
),	O
and	O
the	O
APOE	B-GP
e2	O
SNP	O
rs7412	O
[	O
19	O
]	O
was	O
associated	O
with	O
a	O
genome	O
-	O
wide	O
significant	O
LDL	O
SNP	O
effect	O
(	O
P	O
=	O
1	O
.	O
6	O
×	O
10	O
−	O
8	O
).	O

A	O
region	O
near	O
APOA5	B-GP
that	O
had	O
been	O
previously	O
implicated	O
in	O
triglyceride	O
levels	O
showed	O
a	O
significant	O
SNPxAGE	O
effect	O
on	O
triglycerides	O
in	O
our	O
study	O
(	O
rs12280753	O
;	O
P	O
=	O
1	O
.	O
8	O
×	O
10	O
−	O
8	O
).	O

Although	O
the	O
nearest	O
gene	O
to	O
rs12280753	O
is	O
not	O
APOA5	B-GP
,	O
this	O
SNP	O
was	O
also	O
the	O
most	O
strongly	O
associated	O
SNP	O
in	O
previous	O
studies	O
of	O
adult	O
triglyceride	O
levels	O
[	O
5	O
],	O
[	O
10	O
],	O
[	O
20	O
].	O

Replication	O
in	O
the	O
Young	O
Finns	O

We	O
pursued	O
replication	O
of	O
these	O
findings	O
in	O
genotyped	O
individuals	O
within	O
the	O
Young	O
Finns	O
(	O
YF	O
)	O
cohort	O
,	O
consisting	O
of	O
2	O
,	O
442	O
Finnish	O
individuals	O
tracked	O
from	O
childhood	O
through	O
middle	O
adulthood	O
(	O
ages	O
3	O
–	O
45	O
)	O
with	O
three	O
measures	O
in	O
young	O
individuals	O
(	O
ages	O
3	O
–	O
24	O
)	O
and	O
two	O
measures	O
in	O
older	O
individuals	O
(	O
ages	O
24	O
–	O
45	O
).	O

These	O
individuals	O
have	O
been	O
genotyped	O
on	O
a	O
custom	O
-	O
built	O
Illumina	O
genotyping	O
chip	O
(	O
670K	O
).	O

Using	O
the	O
same	O
analysis	O
methods	O
,	O
we	O
tested	O
whether	O
the	O
top	O
SNP	O
was	O
associated	O
in	O
the	O
YF	O
study	O
(	O
Table	O
3	O
).	O

Imputed	O
genotype	O
dosages	O
were	O
used	O
when	O
direct	O
genotype	O
data	O
was	O
not	O
available	O
.	O

For	O
the	O
APOE	B-GP
-	O
e2	O
SNP	O
rs7412	O
,	O
which	O
is	O
not	O
in	O
HapMap	O
or	O
on	O
the	O
670K	O
chip	O
,	O
we	O
used	O
the	O
SNP	O
with	O
the	O
next	O
strongest	O
association	O
in	O
the	O
BHS	O
(	O
rs445925	O
).	O

There	O
were	O
two	O
SNPs	O
that	O
significantly	O
replicated	O
beyond	O
the	O
multiple	O
testing	O
threshold	O
(	O
P	O
<	O
0	O
.	O
05	O
/	O
51	O
=	O
1	O
×	O
10	O
−	O
3	O
):	O
the	O
rs247616	O
SNP	O
at	O
CETP	B-GP
(	O
P	O
=	O
1	O
.	O
7	O
×	O
10	O
−	O
18	O
),	O
and	O
rs445925	O
at	O
APOE	B-GP
(	O
P	O
=	O
4	O
.	O
1	O
×	O
10	O
−	O
15	O
).	O

There	O
was	O
no	O
trend	O
to	O
replicate	O
the	O
direction	O
of	O
effect	O
between	O
the	O
studies	O
:	O
within	O
the	O
SNP	O
effects	O
,	O
there	O
were	O
12	O
/	O
21	O
(	O
57	O
%,	O
chi	O
-	O
square	O
P	O
=	O
0	O
.	O
51	O
)	O
markers	O
that	O
showed	O
the	O
same	O
direction	O
of	O
effect	O
,	O
while	O
within	O
SNPxAGE	O
effects	O
,	O
there	O
were	O
14	O
/	O
30	O
(	O
47	O
%,	O
chi	O
-	O
square	O
P	O
=	O
0	O
.	O
72	O
).	O

The	O
samples	O
were	O
combined	O
and	O
P	O
-	O
values	O
were	O
calculated	O
for	O
the	O
combined	O
BHS	O
and	O
YF	O
data	O
,	O
using	O
study	O
as	O
a	O
covariate	O
(	O
Table	O
3	O
).	O

The	O
associations	O
at	O
rs247616	O
at	O
CETP	B-GP
with	O
HDL	O
-	O
cholesterol	O
(	O
P	O
=	O
9	O
.	O
7	O
×	O
10	O
−	O
24	O
)	O
and	O
rs445925	O
at	O
APOE	B-GP
with	O
LDL	O
-	O
cholesterol	O
(	O
P	O
=	O
8	O
.	O
7	O
×	O
10	O
−	O
19	O
)	O
were	O
strongly	O
significant	O
,	O
but	O
no	O
other	O
regions	O
in	O
the	O
combined	O
BHS	O
/	O
YF	O
data	O
reached	O
genome	O
-	O
wide	O
significance	O
of	O
P	O
<	O
5	O
×	O
10	O
−	O
8	O
.	O

Replication	O
results	O
in	O
the	O
Young	O
Finns	O
.	O

BHS	O

YF	O

BHS	O
+	O
YF	O
combined	O

Trait	O

Top	O
SNP	O
(	O
Alleles	O
)	O

Effect	O

Beta	O
(	O
SE	O
)	O

P	O

Beta	O
(	O
SE	O
)	O

P	O

Beta	O
(	O
SE	O
)	O

P	O

diastolic	O
BP	O

rs7704530	O
G	O
/	O
A	O

SNP	O

8	O
.	O
44	O
(	O
1	O
.	O
57	O
)	O

1	O
.	O
1	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
05	O
(	O
0	O
.	O
22	O
)	O

0	O
.	O
82	O

0	O
.	O
4	O
(	O
0	O
.	O
2	O
)	O

0	O
.	O
04	O

diastolic	O
BP	O

rs709595	O
C	O
/	O
G	O

SNP	O

7	O
.	O
18	O
(	O
1	O
.	O
43	O
)	O

7	O
.	O
0	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
03	O
(	O
0	O
.	O
21	O
)	O

0	O
.	O
88	O

0	O
.	O
38	O
(	O
0	O
.	O
19	O
)	O

0	O
.	O
04	O

glucose	O

rs853773	O
A	O
/	O
G	O

SNP	O

−	O
8	O
.	O
72	O
(	O
1	O
.	O
73	O
)	O

7	O
.	O
0	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
33	O
(	O
0	O
.	O
37	O
)	O

0	O
.	O
37	O

−	O
0	O
.	O
73	O
(	O
0	O
.	O
32	O
)	O

0	O
.	O
02	O

glucose	O

rs781718	O
*	O
G	O
/	O
A	O

SNP	O

−	O
3	O
.	O
46	O
(	O
0	O
.	O
69	O
)	O

8	O
.	O
4	O
×	O
10	O
−	O
7	O

0	O
.	O
71	O
(	O
0	O
.	O
7	O
)	O

0	O
.	O
31	O

−	O
0	O
.	O
32	O
(	O
0	O
.	O
59	O
)	O

0	O
.	O
58	O

HDL	O
-	O
cholesterol	O

rs247616	O
*	O
T	O
/	O
C	O

SNP	O

3	O
.	O
77	O
(	O
0	O
.	O
75	O
)	O

6	O
.	O
6	O
×	O
10	O
−	O
7	O

2	O
.	O
8	O
(	O
0	O
.	O
32	O
)	O

1	O
.	O
7	O
×	O
10	O
−	O
18	O

2	O
.	O
99	O
(	O
0	O
.	O
29	O
)	O

9	O
.	O
7	O
×	O
10	O
−	O
24	O

insulin	B-GP

rs3793275	O
*	O
A	O
/	O
T	O

SNP	O

−	O
4	O
.	O
63	O
(	O
0	O
.	O
78	O
)	O

5	O
.	O
8	O
×	O
10	O
−	O
9	O

0	O
.	O
36	O
(	O
0	O
.	O
3	O
)	O

0	O
.	O
23	O

−	O
0	O
.	O
13	O
(	O
0	O
.	O
26	O
)	O

0	O
.	O
63	O

insulin	B-GP

rs6052399	O
*	O
T	O
/	O
C	O

SNP	O

−	O
4	O
.	O
55	O
(	O
0	O
.	O
84	O
)	O

9	O
.	O
8	O
×	O
10	O
−	O
8	O

−	O
0	O
.	O
01	O
(	O
0	O
.	O
44	O
)	O

0	O
.	O
99	O

−	O
0	O
.	O
7	O
(	O
0	O
.	O
37	O
)	O

0	O
.	O
06	O

insulin	B-GP

rs16892328	O
*	O
C	O
/	O
T	O

SNP	O

−	O
4	O
.	O
93	O
(	O
0	O
.	O
92	O
)	O

1	O
.	O
3	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
81	O
(	O
0	O
.	O
54	O
)	O

0	O
.	O
14	O

−	O
1	O
.	O
64	O
(	O
0	O
.	O
45	O
)	O

0	O
.	O
00027	O

insulin	B-GP

rs1613695	O
*	O
G	O
/	O
A	O

SNP	O

−	O
5	O
.	O
68	O
(	O
1	O
.	O
07	O
)	O

1	O
.	O
7	O
×	O
10	O
−	O
7	O

0	O
.	O
35	O
(	O
0	O
.	O
36	O
)	O

0	O
.	O
32	O

−	O
0	O
.	O
13	O
(	O
0	O
.	O
31	O
)	O

0	O
.	O
68	O

insulin	B-GP

rs10498337	O
T	O
/	O
G	O

SNP	O

−	O
9	O
.	O
3	O
(	O
1	O
.	O
87	O
)	O

8	O
.	O
9	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
05	O
(	O
0	O
.	O
22	O
)	O

0	O
.	O
81	O

−	O
0	O
.	O
35	O
(	O
0	O
.	O
18	O
)	O

0	O
.	O
06	O

LDL	O
-	O
cholesterol	O

rs8131349	O
*	O
A	O
/	O
G	O

SNP	O

17	O
.	O
6	O
(	O
3	O
.	O
05	O
)	O

1	O
.	O
4	O
×	O
10	O
−	O
8	O

−	O
1	O
.	O
14	O
(	O
1	O
.	O
29	O
)	O

0	O
.	O
38	O

1	O
.	O
46	O
(	O
1	O
.	O
2	O
)	O

0	O
.	O
23	O

LDL	O
-	O
cholesterol	O

rs445925	O
*#	O
G	O
/	O
A	O

SNP	O

12	O
.	O
8	O
(	O
2	O
.	O
63	O
)	O

1	O
.	O
5	O
×	O
10	O
−	O
6	O

12	O
.	O
16	O
(	O
1	O
.	O
54	O
)	O

4	O
.	O
1	O
×	O
10	O
−	O
15	O

11	O
.	O
96	O
(	O
1	O
.	O
34	O
)	O

8	O
.	O
7	O
×	O
10	O
−	O
19	O

LDL	O
-	O
cholesterol	O

rs7738656	O
G	O
/	O
A	O

SNP	O

−	O
42	O
.	O
39	O
(	O
8	O
.	O
11	O
)	O

2	O
.	O
5	O
×	O
10	O
−	O
7	O

−	O
1	O
.	O
52	O
(	O
0	O
.	O
9	O
)	O

0	O
.	O
09	O

−	O
2	O
.	O
91	O
(	O
0	O
.	O
83	O
)	O

0	O
.	O
00049	O

LDL	O
-	O
cholesterol	O

rs10044666	O
*	O
G	O
/	O
T	O

SNP	O

−	O
8	O
.	O
57	O
(	O
1	O
.	O
68	O
)	O

4	O
.	O
7	O
×	O
10	O
−	O
7	O

−	O
1	O
.	O
25	O
(	O
0	O
.	O
91	O
)	O

0	O
.	O
17	O

−	O
2	O
.	O
93	O
(	O
0	O
.	O
81	O
)	O

0	O
.	O
00029	O

systolic	O
BP	O

rs11822822	O
G	O
/	O
A	O

SNP	O

10	O
.	O
74	O
(	O
2	O
.	O
12	O
)	O

5	O
.	O
6	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
34	O
(	O
0	O
.	O
35	O
)	O

0	O
.	O
34	O

0	O
.	O
44	O
(	O
0	O
.	O
3	O
)	O

0	O
.	O
14	O

systolic	O
BP	O

rs726914	O
G	O
/	O
A	O

SNP	O

9	O
.	O
21	O
(	O
1	O
.	O
83	O
)	O

7	O
.	O
1	O
×	O
10	O
−	O
7	O

0	O
.	O
07	O
(	O
0	O
.	O
27	O
)	O

0	O
.	O
81	O

0	O
.	O
55	O
(	O
0	O
.	O
23	O
)	O

0	O
.	O
02	O

total	O
cholesterol	O

rs8131349	O
*	O
A	O
/	O
G	O

SNP	O

18	O
.	O
4	O
(	O
3	O
.	O
32	O
)	O

4	O
.	O
6	O
×	O
10	O
−	O
8	O

−	O
1	O
.	O
26	O
(	O
1	O
.	O
43	O
)	O

0	O
.	O
38	O

1	O
.	O
44	O
(	O
1	O
.	O
32	O
)	O

0	O
.	O
28	O

total	O
cholesterol	O

rs6829649	O
T	O
/	O
G	O

SNP	O

−	O
50	O
.	O
96	O
(	O
9	O
.	O
42	O
)	O

9	O
.	O
6	O
×	O
10	O
−	O
8	O

0	O
.	O
09	O
(	O
1	O
.	O
23	O
)	O

0	O
.	O
94	O

−	O
2	O
.	O
06	O
(	O
1	O
.	O
1	O
)	O

0	O
.	O
06	O

total	O
cholesterol	O

rs7738656	O
G	O
/	O
A	O

SNP	O

−	O
46	O
.	O
21	O
(	O
8	O
.	O
79	O
)	O

2	O
.	O
1	O
×	O
10	O
−	O
7	O

−	O
1	O
.	O
51	O
(	O
1	O
)	O

0	O
.	O
13	O

−	O
3	O
.	O
04	O
(	O
0	O
.	O
92	O
)	O

0	O
.	O
00094	O

total	O
cholesterol	O

rs4897695	O
*	O
C	O
/	O
G	O

SNP	O

13	O
.	O
66	O
(	O
2	O
.	O
62	O
)	O

2	O
.	O
7	O
×	O
10	O
−	O
7	O

0	O
.	O
51	O
(	O
1	O
.	O
7	O
)	O

0	O
.	O
76	O

4	O
.	O
14	O
(	O
1	O
.	O
44	O
)	O

0	O
.	O
0041	O

waist	O
circumference	O

rs891541	O
*	O
A	O
/	O
G	O

SNP	O

4	O
.	O
55	O
(	O
0	O
.	O
91	O
)	O

7	O
.	O
7	O
×	O
10	O
−	O
7	O

0	O
.	O
28	O
(	O
0	O
.	O
37	O
)	O

0	O
.	O
44	O

1	O
.	O
18	O
(	O
0	O
.	O
35	O
)	O

0	O
.	O
00076	O

distolic	O
BP	O

rs17104804	O
G	O
/	O
A	O

SNPxAGE	O

−	O
0	O
.	O
76	O
(	O
0	O
.	O
15	O
)	O

5	O
.	O
9	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
02	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
63	O

−	O
0	O
.	O
1	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
00047	O

glucose	O

rs4783595	O
T	O
/	O
C	O

SNPxAGE	O

−	O
1	O
.	O
67	O
(	O
0	O
.	O
31	O
)	O

9	O
.	O
5	O
×	O
10	O
−	O
8	O

−	O
0	O
.	O
04	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
29	O

−	O
0	O
.	O
12	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
00021	O

glucose	O

rs3793275	O
*	O
A	O
/	O
T	O

SNPxAGE	O

−	O
0	O
.	O
61	O
(	O
0	O
.	O
12	O
)	O

1	O
.	O
5	O
×	O
10	O
−	O
7	O

0	O
.	O
04	O
(	O
0	O
.	O
05	O
)	O

0	O
.	O
43	O

−	O
0	O
.	O
09	O
(	O
0	O
.	O
05	O
)	O

0	O
.	O
05	O

glucose	O

rs5979903	O
T	O
/	O
C	O

SNPxAGE	O

1	O
.	O
88	O
(	O
0	O
.	O
36	O
)	O

1	O
.	O
9	O
×	O
10	O
−	O
7	O

0	O
.	O
08	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
07	O

0	O
.	O
16	O
(	O
0	O
.	O
04	O
)	O

9	O
.	O
8	O
×	O
10	O
−	O
5	O

glucose	O

rs12807555	O
*	O
G	O
/	O
T	O

SNPxAGE	O

−	O
0	O
.	O
47	O
(	O
0	O
.	O
09	O
)	O

2	O
.	O
7	O
×	O
10	O
−	O
7	O

0	O
.	O
01	O
(	O
0	O
.	O
05	O
)	O

0	O
.	O
78	O

−	O
0	O
.	O
1	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
02	O

glucose	O

rs9909931	O
G	O
/	O
A	O

SNPxAGE	O

1	O
.	O
36	O
(	O
0	O
.	O
27	O
)	O

4	O
.	O
3	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
02	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
56	O

0	O
.	O
06	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
06	O

glucose	O

rs12069004	O
*	O
C	O
/	O
T	O

SNPxAGE	O

−	O
0	O
.	O
54	O
(	O
0	O
.	O
11	O
)	O

5	O
.	O
8	O
×	O
10	O
−	O
7	O

0	O
.	O
02	O
(	O
0	O
.	O
05	O
)	O

0	O
.	O
7	O

−	O
0	O
.	O
1	O
(	O
0	O
.	O
05	O
)	O

0	O
.	O
03	O

glucose	O

rs12548494	O
*	O
C	O
/	O
G	O

SNPxAGE	O

−	O
0	O
.	O
6	O
(	O
0	O
.	O
12	O
)	O

7	O
.	O
1	O
×	O
10	O
−	O
7	O

1	O
.	O
4	O
×	O
10	O
−	O
4	O
(	O
0	O
.	O
09	O
)	O

1	O

−	O
0	O
.	O
18	O
(	O
0	O
.	O
07	O
)	O

0	O
.	O
01	O

glucose	O

rs10260737	O
G	O
/	O
A	O

SNPxAGE	O

−	O
1	O
.	O
77	O
(	O
0	O
.	O
36	O
)	O

7	O
.	O
3	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
02	O
(	O
0	O
.	O
06	O
)	O

0	O
.	O
8	O

−	O
0	O
.	O
11	O
(	O
0	O
.	O
05	O
)	O

0	O
.	O
03	O

glucose	O

rs3019325	O
*	O
G	O
/	O
C	O

SNPxAGE	O

−	O
0	O
.	O
31	O
(	O
0	O
.	O
06	O
)	O

7	O
.	O
5	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
02	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
55	O

−	O
0	O
.	O
07	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
0097	O

heart	O
rate	O

rs6440031	O
G	O
/	O
A	O

SNPxAGE	O

1	O
.	O
33	O
(	O
0	O
.	O
25	O
)	O

1	O
.	O
8	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
01	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
72	O

0	O
.	O
03	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
16	O

heart	O
rate	O

rs1449460	O
G	O
/	O
A	O

SNPxAGE	O

−	O
1	O
.	O
36	O
(	O
0	O
.	O
27	O
)	O

7	O
.	O
4	O
×	O
10	O
−	O
7	O

0	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
93	O

−	O
0	O
.	O
05	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
1	O

height	O

rs1144036	O
C	O
/	O
T	O

SNPxAGE	O

1	O
.	O
17	O
(	O
0	O
.	O
23	O
)	O

2	O
.	O
4	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
07	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
09	O

0	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
91	O

height	O

rs8103264	O
*	O
C	O
/	O
G	O

SNPxAGE	O

−	O
0	O
.	O
38	O
(	O
0	O
.	O
08	O
)	O

5	O
.	O
6	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
04	O
(	O
0	O
.	O
06	O
)	O

0	O
.	O
42	O

−	O
0	O
.	O
11	O
(	O
0	O
.	O
05	O
)	O

0	O
.	O
02	O

insulin	B-GP

rs1552257	O
*	O
C	O
/	O
T	O

SNPxAGE	O

0	O
.	O
18	O
(	O
0	O
.	O
04	O
)	O

7	O
.	O
5	O
×	O
10	O
−	O
7	O

0	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
79	O

0	O
.	O
02	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
27	O

LDL	O

rs8073909	O
T	O
/	O
C	O

SNPxAGE	O

−	O
1	O
.	O
41	O
(	O
0	O
.	O
27	O
)	O

1	O
.	O
4	O
×	O
10	O
−	O
7	O

0	O
.	O
06	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
08	O

0	O
.	O
04	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
32	O

LDL	O

rs11258628	O
*	O
A	O
/	O
T	O

SNPxAGE	O

−	O
0	O
.	O
69	O
(	O
0	O
.	O
14	O
)	O

4	O
.	O
1	O
×	O
10	O
−	O
7	O

0	O
.	O
02	O
(	O
0	O
.	O
09	O
)	O

0	O
.	O
84	O

−	O
0	O
.	O
38	O
(	O
0	O
.	O
09	O
)	O

1	O
.	O
8	O
×	O
10	O
−	O
5	O

systolic	O
BP	O

rs1046391	O
*	O
G	O
/	O
T	O

SNPxAGE	O

0	O
.	O
21	O
(	O
0	O
.	O
04	O
)	O

4	O
.	O
1	O
×	O
10	O
−	O
7	O

0	O
.	O
01	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
78	O

0	O
.	O
05	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
03	O

systolic	O
BP	O

rs17104804	O
G	O
/	O
A	O

SNPxAGE	O

−	O
0	O
.	O
91	O
(	O
0	O
.	O
19	O
)	O

9	O
.	O
3	O
×	O
10	O
−	O
7	O

0	O
.	O
01	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
63	O

−	O
0	O
.	O
05	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
06	O

total	O
cholesterol	O

rs8073909	O
T	O
/	O
C	O

SNPxAGE	O

−	O
1	O
.	O
68	O
(	O
0	O
.	O
31	O
)	O

6	O
.	O
9	O
×	O
10	O
−	O
8	O

0	O
.	O
06	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
13	O

0	O
.	O
03	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
51	O

triglycerides	O

rs7890572	O
G	O
/	O
A	O

SNPxAGE	O

9	O
.	O
75	O
(	O
1	O
.	O
55	O
)	O

3	O
.	O
8	O
×	O
10	O
−	O
10	O

0	O
.	O
1	O
(	O
0	O
.	O
22	O
)	O

0	O
.	O
66	O

0	O
.	O
97	O
(	O
0	O
.	O
18	O
)	O

1	O
.	O
2	O
×	O
10	O
−	O
7	O

triglycerides	O

rs12280753	O
*	O
T	O
/	O
C	O

SNPxAGE	O

2	O
.	O
64	O
(	O
0	O
.	O
47	O
)	O

1	O
.	O
8	O
×	O
10	O
−	O
8	O

0	O
.	O
28	O
(	O
0	O
.	O
16	O
)	O

0	O
.	O
09	O

0	O
.	O
69	O
(	O
0	O
.	O
15	O
)	O

7	O
.	O
8	O
×	O
10	O
−	O
6	O

triglycerides	O

rs13290397	O
*	O
C	O
/	O
G	O

SNPxAGE	O

−	O
1	O
.	O
98	O
(	O
0	O
.	O
38	O
)	O

2	O
.	O
4	O
×	O
10	O
−	O
7	O

0	O
.	O
21	O
(	O
0	O
.	O
15	O
)	O

0	O
.	O
17	O

−	O
0	O
.	O
25	O
(	O
0	O
.	O
14	O
)	O

0	O
.	O
08	O

triglycerides	O

rs6726786	O
*	O
G	O
/	O
T	O

SNPxAGE	O

−	O
2	O
.	O
09	O
(	O
0	O
.	O
41	O
)	O

2	O
.	O
9	O
×	O
10	O
−	O
7	O

0	O
.	O
1	O
(	O
0	O
.	O
15	O
)	O

0	O
.	O
49	O

−	O
0	O
.	O
32	O
(	O
0	O
.	O
14	O
)	O

0	O
.	O
02	O

triglycerides	O

rs12330441	O
T	O
/	O
G	O

SNPxAGE	O

−	O
9	O
.	O
54	O
(	O
1	O
.	O
86	O
)	O

3	O
.	O
0	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
05	O
(	O
0	O
.	O
16	O
)	O

0	O
.	O
75	O

−	O
0	O
.	O
47	O
(	O
0	O
.	O
16	O
)	O

0	O
.	O
0025	O

waist	O
circumference	O

rs127430	O
*	O
G	O
/	O
A	O

SNPxAGE	O

−	O
0	O
.	O
33	O
(	O
0	O
.	O
06	O
)	O

3	O
.	O
3	O
×	O
10	O
−	O
8	O

−	O
0	O
.	O
02	O
(	O
0	O
.	O
05	O
)	O

0	O
.	O
65	O

−	O
0	O
.	O
19	O
(	O
0	O
.	O
04	O
)	O

1	O
.	O
4	O
×	O
10	O
−	O
6	O

waist	O
circumference	O

rs7121446	O
G	O
/	O
A	O

SNPxAGE	O

−	O
1	O
.	O
09	O
(	O
0	O
.	O
21	O
)	O

3	O
.	O
6	O
×	O
10	O
−	O
7	O

−	O
0	O
.	O
07	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
11	O

−	O
0	O
.	O
15	O
(	O
0	O
.	O
03	O
)	O

2	O
.	O
5	O
×	O
10	O
−	O
6	O

waist	O
circumference	O

rs7210277	O
*	O
C	O
/	O
T	O

SNPxAGE	O

−	O
0	O
.	O
39	O
(	O
0	O
.	O
08	O
)	O

7	O
.	O
0	O
×	O
10	O
−	O
7	O

0	O
.	O
04	O
(	O
0	O
.	O
06	O
)	O

0	O
.	O
48	O

−	O
0	O
.	O
17	O
(	O
0	O
.	O
05	O
)	O

0	O
.	O
00043	O

waist	O
circumference	O

rs17568778	O
C	O
/	O
A	O

SNPxAGE	O

−	O
1	O
.	O
55	O
(	O
0	O
.	O
31	O
)	O

8	O
.	O
2	O
×	O
10	O
−	O
7	O

0	O
(	O
0	O
.	O
06	O
)	O

0	O
.	O
98	O

−	O
0	O
.	O
17	O
(	O
0	O
.	O
05	O
)	O

0	O
.	O
00024	O

weight	O

rs6552560	O
T	O
/	O
C	O

SNPxAGE	O

1	O
.	O
35	O
(	O
0	O
.	O
25	O
)	O

8	O
.	O
5	O
×	O
10	O
−	O
8	O

−	O
0	O
.	O
02	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
5	O

0	O
.	O
06	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
03	O

Replication	O
effects	O
and	O
P	O
-	O
values	O
in	O
the	O
Young	O
Finns	O
(	O
YF	O
)	O
Study	O
and	O
in	O
combined	O
data	O
,	O
adjusted	O
for	O
study	O
.	O

SNP	O
names	O
marked	O
with	O
an	O
“*”	O
are	O
imputed	O
,	O
while	O
those	O
that	O
are	O
unmarked	O
were	O
directly	O
genotyped	O
.	O

SNP	O
alleles	O
are	O
reported	O
as	O
risk	O
/	O
nonrisk	O
and	O
are	O
in	O
genome	O
forward	O
orientation	O
(	O
build	O
36	O
.	O
3	O
).	O
#	O
rs445925	O
is	O
a	O
proxy	O
for	O
rs7412	O
.	O

Prediction	O
of	O
adult	O
values	O
given	O
childhood	O
values	O

Genetic	O
variants	O
will	O
be	O
most	O
useful	O
for	O
trait	O
prediction	O
when	O
they	O
are	O
associated	O
with	O
a	O
trait	O
above	O
and	O
beyond	O
other	O
known	O
risk	O
factors	O
.	O

In	O
addition	O
,	O
the	O
ability	O
to	O
predict	O
adult	O
trait	O
levels	O
in	O
children	O
,	O
before	O
disease	O
onset	O
,	O
can	O
lead	O
to	O
a	O
disease	O
prevention	O
strategy	O
.	O

In	O
longitudinal	O
studies	O
starting	O
in	O
childhood	O
and	O
going	O
into	O
adulthood	O
,	O
we	O
can	O
ask	O
whether	O
genetic	O
loci	O
are	O
associated	O
with	O
the	O
adult	O
trait	O
level	O
above	O
and	O
beyond	O
the	O
trait	O
level	O
seen	O
in	O
the	O
first	O
measure	O
taken	O
in	O
childhood	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
evaluated	O
whether	O
our	O
associated	O
markers	O
were	O
likely	O
to	O
be	O
predictive	O
of	O
adult	O
levels	O
of	O
the	O
traits	O
,	O
after	O
adjustment	O
for	O
trait	O
levels	O
in	O
childhood	O
.	O

To	O
account	O
for	O
variation	O
in	O
data	O
collection	O
,	O
we	O
also	O
included	O
the	O
age	O
at	O
each	O
of	O
these	O
measures	O
as	O
well	O
as	O
gender	O
as	O
covariates	O
in	O
the	O
analysis	O
.	O

Within	O
the	O
BHS	O
,	O
variants	O
that	O
were	O
characterized	O
as	O
SNPxAGE	O
effects	O
were	O
more	O
likely	O
to	O
be	O
predictive	O
of	O
adult	O
values	O
after	O
correcting	O
for	O
childhood	O
values	O
,	O
which	O
is	O
expected	O
since	O
these	O
variants	O
were	O
characterized	O
in	O
BHS	O
initially	O
(	O
Table	O
4	O
).	O

In	O
the	O
YF	O
study	O
,	O
however	O
,	O
we	O
also	O
saw	O
more	O
SNPxAGE	O
variants	O
associated	O
with	O
adult	O
levels	O
given	O
childhood	O
levels	O
(	O
Table	O
4	O
).	O

There	O
were	O
6	O
variants	O
that	O
were	O
associated	O
with	O
adult	O
levels	O
in	O
the	O
YF	O
study	O
at	O
P	O
<	O
0	O
.	O
05	O
,	O
with	O
2	O
corresponding	O
to	O
the	O
genome	O
-	O
wide	O
significant	O
SNP	O
effects	O
and	O
4	O
corresponding	O
to	O
BHS	O
SNPxAGE	O
variants	O
.	O

Only	O
the	O
association	O
of	O
rs445925	O
with	O
LDL	O
-	O
cholesterol	O
was	O
strong	O
enough	O
to	O
withstand	O
multiple	O
corrections	O
.	O

Further	O
analysis	O
of	O
this	O
observation	O
is	O
warranted	O
in	O
a	O
larger	O
cohort	O
.	O

Association	O
of	O
GWAS	O
SNPs	O
with	O
adult	O
trait	O
levels	O
after	O
adjusting	O
for	O
childhood	O
levels	O
.	O

Trait	O

Top	O
SNP	O
(	O
Alleles	O
)	O

Effect	O

BHS	O
Adult	O
prediction	O
P	O

YF	O
Adult	O
prediction	O
P	O

diastolic	O
BP	O

rs7704530	O
G	O
/	O
A	O

SNP	O

0	O
.	O
07	O

0	O
.	O
74	O

diastolic	O
BP	O

rs709595	O
C	O
/	O
G	O

SNP	O

0	O
.	O
26	O

0	O
.	O
09	O

glucose	O

rs853773	O
A	O
/	O
G	O

SNP	O

0	O
.	O
003	O

0	O
.	O
24	O

glucose	O

rs781718	O
*	O
G	O
/	O
A	O

SNP	O

0	O
.	O
27	O

0	O
.	O
21	O

HDL	O
-	O
cholesterol	O

rs247616	O
*	O
T	O
/	O
C	O

SNP	O

8	O
.	O
1	O
×	O
10	O
−	O
4	O

0	O
.	O
0067	O

insulin	B-GP

rs3793275	O
*	O
A	O
/	O
T	O

SNP	O

0	O
.	O
89	O

0	O
.	O
36	O

insulin	B-GP

rs6052399	O
*	O
T	O
/	O
C	O

SNP	O

0	O
.	O
014	O

0	O
.	O
89	O

insulin	B-GP

rs16892328	O
*	O
C	O
/	O
T	O

SNP	O

0	O
.	O
22	O

0	O
.	O
14	O

insulin	B-GP

rs1613695	O
*	O
G	O
/	O
A	O

SNP	O

0	O
.	O
16	O

0	O
.	O
67	O

insulin	B-GP

rs10498337	O
T	O
/	O
G	O

SNP	O

0	O
.	O
38	O

0	O
.	O
88	O

LDL	O
-	O
cholesterol	O

rs8131349	O
*	O
A	O
/	O
G	O

SNP	O

0	O
.	O
14	O

0	O
.	O
16	O

LDL	O
-	O
cholesterol	O

rs445925	O
*	O
G	O
/	O
A	O

SNP	O

0	O
.	O
025	O

2	O
.	O
3	O
×	O
10	O
−	O
6	O

LDL	O
-	O
cholesterol	O

rs7738656	O
G	O
/	O
A	O

SNP	O

0	O
.	O
042	O

0	O
.	O
25	O

LDL	O
-	O
cholesterol	O

rs10044666	O
*	O
G	O
/	O
T	O

SNP	O

0	O
.	O
015	O

0	O
.	O
78	O

systolic	O
BP	O

rs11822822	O
G	O
/	O
A	O

SNP	O

0	O
.	O
002	O

0	O
.	O
63	O

systolic	O
BP	O

rs726914	O
G	O
/	O
A	O

SNP	O

0	O
.	O
004	O

0	O
.	O
54	O

total	O
cholesterol	O

rs8131349	O
*	O
A	O
/	O
G	O

SNP	O

0	O
.	O
051	O

0	O
.	O
3	O

total	O
cholesterol	O

rs6829649	O
T	O
/	O
G	O

SNP	O

0	O
.	O
56	O

0	O
.	O
44	O

total	O
cholesterol	O

rs7738656	O
G	O
/	O
A	O

SNP	O

0	O
.	O
028	O

0	O
.	O
08	O

total	O
cholesterol	O

rs4897695	O
*	O
C	O
/	O
G	O

SNP	O

0	O
.	O
24	O

0	O
.	O
91	O

waist	O
circumference	O

rs891541	O
*	O
A	O
/	O
G	O

SNP	O

0	O
.	O
14	O

0	O
.	O
28	O

distolic	O
BP	O

rs17104804	O
G	O
/	O
A	O

SNPxAGE	O

1	O
.	O
5	O
×	O
10	O
−	O
4	O

0	O
.	O
46	O

glucose	O

rs4783595	O
T	O
/	O
C	O

SNPxAGE	O

8	O
.	O
7	O
×	O
10	O
−	O
8	O

0	O
.	O
4	O

glucose	O

rs3793275	O
*	O
A	O
/	O
T	O

SNPxAGE	O

5	O
.	O
7	O
×	O
10	O
−	O
7	O

0	O
.	O
44	O

glucose	O

rs5979903	O
T	O
/	O
C	O

SNPxAGE	O

3	O
.	O
0	O
×	O
10	O
−	O
4	O

0	O
.	O
45	O

glucose	O

rs12807555	O
*	O
G	O
/	O
T	O

SNPxAGE	O

1	O
.	O
2	O
×	O
10	O
−	O
8	O

0	O
.	O
93	O

glucose	O

rs9909931	O
G	O
/	O
A	O

SNPxAGE	O

5	O
.	O
0	O
×	O
10	O
−	O
7	O

0	O
.	O
67	O

glucose	O

rs12069004	O
*	O
C	O
/	O
T	O

SNPxAGE	O

3	O
.	O
2	O
×	O
10	O
−	O
5	O

0	O
.	O
88	O

glucose	O

rs12548494	O
*	O
C	O
/	O
G	O

SNPxAGE	O

2	O
.	O
7	O
×	O
10	O
−	O
6	O

0	O
.	O
45	O

glucose	O

rs10260737	O
G	O
/	O
A	O

SNPxAGE	O

1	O
.	O
2	O
×	O
10	O
−	O
5	O

1	O

glucose	O

rs3019325	O
*	O
G	O
/	O
C	O

SNPxAGE	O

2	O
.	O
2	O
×	O
10	O
−	O
5	O

0	O
.	O
56	O

heart	O
rate	O

rs6440031	O
G	O
/	O
A	O

SNPxAGE	O

1	O
.	O
2	O
×	O
10	O
−	O
3	O

0	O
.	O
77	O

heart	O
rate	O

rs1449460	O
G	O
/	O
A	O

SNPxAGE	O

0	O
.	O
0302	O

0	O
.	O
81	O

height	O

rs1144036	O
C	O
/	O
T	O

SNPxAGE	O

0	O
.	O
2199	O

0	O
.	O
01	O

height	O

rs8103264	O
*	O
C	O
/	O
G	O

SNPxAGE	O

0	O
.	O
0360	O

0	O
.	O
49	O

insulin	B-GP

rs1552257	O
*	O
C	O
/	O
T	O

SNPxAGE	O

3	O
.	O
8	O
×	O
10	O
−	O
5	O

0	O
.	O
61	O

LDL	O

rs8073909	O
T	O
/	O
C	O

SNPxAGE	O

1	O
.	O
2	O
×	O
10	O
−	O
6	O

0	O
.	O
007	O

LDL	O

rs11258628	O
*	O
A	O
/	O
T	O

SNPxAGE	O

7	O
.	O
3	O
×	O
10	O
−	O
6	O

0	O
.	O
88	O

systolic	O
BP	O

rs1046391	O
*	O
G	O
/	O
T	O

SNPxAGE	O

6	O
.	O
2	O
×	O
10	O
−	O
4	O

0	O
.	O
74	O

systolic	O
BP	O

rs17104804	O
G	O
/	O
A	O

SNPxAGE	O

0	O
.	O
0015	O

0	O
.	O
36	O

total	O
cholesterol	O

rs8073909	O
T	O
/	O
C	O

SNPxAGE	O

2	O
.	O
0	O
×	O
10	O
−	O
7	O

0	O
.	O
008	O

triglycerides	O

rs7890572	O
G	O
/	O
A	O

SNPxAGE	O

4	O
.	O
2	O
×	O
10	O
−	O
6	O

0	O
.	O
43	O

triglycerides	O

rs12280753	O
*	O
T	O
/	O
C	O

SNPxAGE	O

9	O
.	O
9	O
×	O
10	O
−	O
9	O

0	O
.	O
24	O

triglycerides	O

rs13290397	O
*	O
C	O
/	O
G	O

SNPxAGE	O

6	O
.	O
8	O
×	O
10	O
−	O
7	O

0	O
.	O
33	O

triglycerides	O

rs6726786	O
*	O
G	O
/	O
T	O

SNPxAGE	O

3	O
.	O
9	O
×	O
10	O
−	O
6	O

0	O
.	O
74	O

triglycerides	O

rs12330441	O
T	O
/	O
G	O

SNPxAGE	O

3	O
.	O
1	O
×	O
10	O
−	O
5	O

0	O
.	O
79	O

waist	O
circumference	O

rs127430	O
*	O
G	O
/	O
A	O

SNPxAGE	O

2	O
.	O
1	O
×	O
10	O
−	O
7	O

0	O
.	O
71	O

waist	O
circumference	O

rs7121446	O
G	O
/	O
A	O

SNPxAGE	O

2	O
.	O
2	O
×	O
10	O
−	O
6	O

0	O
.	O
68	O

waist	O
circumference	O

rs7210277	O
*	O
C	O
/	O
T	O

SNPxAGE	O

1	O
.	O
2	O
×	O
10	O
−	O
6	O

0	O
.	O
9	O

waist	O
circumference	O

rs17568778	O
C	O
/	O
A	O

SNPxAGE	O

9	O
.	O
0	O
×	O
10	O
−	O
7	O

0	O
.	O
99	O

weight	O

rs6552560	O
T	O
/	O
C	O

SNPxAGE	O

1	O
.	O
8	O
×	O
10	O
−	O
5	O

0	O
.	O
04	O

Adult	O
prediction	O
P	O
-	O
values	O
correspond	O
to	O
the	O
association	O
between	O
the	O
SNP	O
and	O
the	O
last	O
adult	O
measurement	O
,	O
after	O
adjusting	O
for	O
the	O
first	O
measure	O
in	O
childhood	O
.	O

Previously	O
identified	O
markers	O

We	O
assessed	O
whether	O
associations	O
that	O
have	O
been	O
described	O
in	O
previous	O
adult	O
cross	O
-	O
sectional	O
GWA	O
studies	O
exhibit	O
consistent	O
effects	O
over	O
time	O
and	O
whether	O
the	O
effect	O
sizes	O
observed	O
in	O
children	O
through	O
middle	O
-	O
aged	O
adults	O
are	O
consistent	O
with	O
those	O
previously	O
described	O
.	O

We	O
identified	O
169	O
SNP	O
-	O
trait	O
associations	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
for	O
which	O
we	O
had	O
directly	O
genotyped	O
or	O
imputed	O
genotype	O
data	O
.	O

We	O
first	O
estimated	O
our	O
power	O
to	O
detect	O
each	O
previous	O
association	O
at	O
alpha	O
=	O
0	O
.	O
05	O
under	O
a	O
more	O
structured	O
,	O
but	O
similar	O
study	O
design	O
(	O
i	O
.	O
e	O
.,	O
8	O
equally	O
spaced	O
measurements	O
),	O
given	O
the	O
previously	O
reported	O
effect	O
size	O
and	O
allele	O
frequency	O
.	O

Under	O
this	O
model	O
,	O
we	O
would	O
expect	O
to	O
have	O
detected	O
40	O
/	O
169	O
(	O
24	O
%)	O
associations	O
at	O
P	O
<	O
0	O
.	O
05	O
,	O
and	O
we	O
observed	O
a	O
similar	O
number	O
of	O
SNP	O
effects	O
in	O
the	O
BHS	O
data	O
(	O
32	O
/	O
169	O
;	O
19	O
%).	O

We	O
evaluated	O
the	O
associations	O
across	O
all	O
traits	O
together	O
by	O
comparing	O
how	O
well	O
the	O
previously	O
reported	O
effect	O
size	O
was	O
recapitulated	O
in	O
the	O
BHS	O
GWA	O
(	O
Figure	O
1A	O
).	O

For	O
consistency	O
across	O
studies	O
and	O
traits	O
,	O
if	O
an	O
effect	O
size	O
was	O
not	O
already	O
expressed	O
in	O
terms	O
of	O
percent	O
standard	O
deviation	O
(%	O
SD	O
),	O
we	O
converted	O
the	O
previously	O
reported	O
effect	O
size	O
into	O
%	O
SD	O
and	O
compared	O
the	O
previous	O
effect	O
size	O
to	O
the	O
SNP	O
effect	O
.	O

The	O
previously	O
reported	O
effect	O
size	O
was	O
a	O
strong	O
predictor	O
of	O
the	O
SNP	O
effect	O
(	O
slope	O
=	O
0	O
.	O
47	O
,	O
P	O
=	O
1	O
.	O
2	O
×	O
10	O
−	O
21	O
),	O
suggesting	O
that	O
SNPs	O
that	O
have	O
been	O
previously	O
identified	O
in	O
adult	O
cross	O
-	O
sectional	O
GWA	O
studies	O
are	O
good	O
predictors	O
of	O
time	O
-	O
averaged	O
effects	O
in	O
the	O
BHS	O
sample	O
.	O

Effects	O
of	O
previously	O
identified	O
variants	O
in	O
the	O
BHS	O
.	O

A	O
)	O
Effect	O
sizes	O
of	O
previously	O
identified	O
markers	O
are	O
plotted	O
against	O
observed	O
effects	O
in	O
the	O
BHS	O
.	O

SNP	O
-	O
trait	O
associations	O
are	O
plotted	O
by	O
shape	O
and	O
color	O
to	O
indicate	O
trait	O
.	O

The	O
size	O
of	O
the	O
point	O
indicates	O
the	O
power	O
to	O
detect	O
an	O
association	O
of	O
the	O
magnitude	O
previously	O
described	O
,	O
and	O
whether	O
a	O
point	O
is	O
filled	O
in	O
or	O
not	O
indicates	O
whether	O
the	O
association	O
was	O
significant	O
at	O
P	O
<	O
0	O
.	O
05	O
in	O
the	O
BHS	O
.	O

Linear	O
regression	O
lines	O
are	O
shown	O
,	O
with	O
the	O
slope	O
and	O
p	O
-	O
value	O
of	O
the	O
association	O
between	O
previously	O
reported	O
effect	O
sizes	O
and	O
the	O
observed	O
effect	O
sizes	O
.	O

B	O
)	O
Individuals	O
were	O
scored	O
based	O
on	O
the	O
effect	O
size	O
of	O
each	O
previously	O
identified	O
marker	O
and	O
are	O
grouped	O
and	O
color	O
-	O
coded	O
based	O
on	O
the	O
decile	O
of	O
their	O
score	O
.	O

Linear	O
lines	O
are	O
linear	O
regression	O
estimates	O
of	O
the	O
average	O
trajectory	O
of	O
each	O
decile	O
group	O
.	O

We	O
also	O
determined	O
whether	O
the	O
same	O
previously	O
identified	O
SNPs	O
were	O
likely	O
to	O
show	O
effects	O
on	O
a	O
trait	O
over	O
time	O
(	O
SNPxAGE	O
effects	O
).	O

Under	O
a	O
simple	O
model	O
that	O
assumed	O
that	O
all	O
of	O
the	O
effect	O
in	O
adults	O
is	O
due	O
to	O
a	O
locus	O
that	O
has	O
no	O
effect	O
in	O
childhood	O
,	O
we	O
estimated	O
power	O
to	O
detect	O
such	O
an	O
interaction	O
effect	O
in	O
a	O
similarly	O
structured	O
study	O
with	O
8	O
repeated	O
measures	O
.	O

Given	O
these	O
assumptions	O
,	O
we	O
would	O
have	O
expected	O
to	O
see	O
24	O
/	O
169	O
(	O
14	O
%)	O
SNPxAGE	O
associations	O
.	O

We	O
observed	O
6	O
/	O
169	O
(	O
3	O
.	O
6	O
%)	O
SNPs	O
that	O
showed	O
SNPxAGE	O
effects	O
at	O
P	O
<	O
0	O
.	O
05	O
,	O
indicating	O
that	O
effects	O
seen	O
in	O
SNPs	O
described	O
in	O
adult	O
GWA	O
studies	O
are	O
not	O
due	O
primarily	O
to	O
differences	O
in	O
effects	O
over	O
time	O
,	O
although	O
larger	O
studies	O
will	O
be	O
required	O
to	O
definitively	O
characterize	O
this	O
.	O

Composite	O
scoring	O

We	O
considered	O
whether	O
a	O
composite	O
genotype	O
score	O
would	O
better	O
predict	O
overall	O
CVD	B-DS
risk	O
factor	O
trajectories	O
or	O
time	O
-	O
dependent	O
effects	O
than	O
any	O
single	O
locus	O
.	O

For	O
each	O
person	O
and	O
each	O
trait	O
,	O
we	O
created	O
a	O
score	O
by	O
summing	O
the	O
expected	O
effect	O
in	O
percent	O
standard	O
deviation	O
of	O
each	O
allele	O
that	O
the	O
person	O
carried	O
.	O

We	O
then	O
determined	O
whether	O
the	O
score	O
was	O
associated	O
with	O
the	O
trait	O
'	O
s	O
average	O
value	O
and	O
trajectory	O
by	O
using	O
this	O
score	O
as	O
a	O
predictor	O
for	O
each	O
trait	O
in	O
a	O
linear	O
mixed	O
model	O
,	O
adjusting	O
for	O
age	O
and	O
gender	O
.	O

We	O
assessed	O
the	O
score	O
'	O
s	O
average	O
effect	O
across	O
time	O
(	O
score	O
effect	O
)	O
and	O
whether	O
or	O
not	O
there	O
was	O
a	O
time	O
-	O
dependent	O
effect	O
(	O
score	O
*	O
age	O
effect	O
).	O

The	O
traits	O
HDL	O
,	O
LDL	O
,	O
total	O
cholesterol	O
,	O
triglycerides	O
,	O
and	O
height	O
showed	O
strongly	O
significant	O
score	O
effects	O
,	O
while	O
only	O
triglycerides	O
showed	O
a	O
score	O
*	O
age	O
effect	O
(	O
Table	O
5	O
).	O

Longitudinal	O
data	O
was	O
visualized	O
by	O
color	O
-	O
coding	O
the	O
individuals	O
according	O
to	O
the	O
decile	O
of	O
their	O
overall	O
score	O
and	O
the	O
average	O
linear	O
trend	O
of	O
each	O
group	O
was	O
plotted	O
(	O
LDL	O
,	O
Figure	O
1B	O
and	O
others	O
in	O
Figure	O
S3	O
).	O

These	O
results	O
indicate	O
that	O
the	O
cumulative	O
effects	O
of	O
SNPs	O
that	O
are	O
identified	O
in	O
large	O
adult	O
cross	O
-	O
sectional	O
studies	O
are	O
generally	O
age	O
-	O
independent	O
effects	O
,	O
with	O
an	O
exception	O
in	O
triglycerides	O
,	O
which	O
was	O
the	O
only	O
trait	O
to	O
show	O
a	O
significant	O
score	O
*	O
age	O
effect	O
.	O

We	O
additionally	O
tested	O
whether	O
previously	O
identified	O
variants	O
were	O
predictive	O
of	O
adult	O
levels	O
after	O
adjusting	O
for	O
childhood	O
levels	O
(	O
Table	O
6	O
).	O

We	O
saw	O
that	O
25	O
/	O
169	O
(	O
14	O
.	O
8	O
%)	O
showed	O
association	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

These	O
observations	O
in	O
the	O
BHS	O
data	O
suggest	O
that	O
even	O
though	O
results	O
from	O
existing	O
GWA	O
studies	O
demonstrate	O
age	O
-	O
independent	O
effects	O
,	O
they	O
can	O
be	O
predictive	O
of	O
trait	O
values	O
in	O
adults	O
.	O

P	O
-	O
values	O
associated	O
with	O
score	O
and	O
score	O
*	O
age	O
effects	O
(	O
Age	O
and	O
Sex	O
adjusted	O
).	O

Score	O

Score	O
×	O
AGE	O

weight	O

0	O
.	O
03	O

0	O
.	O
11	O

diastolic	O
BP	O

0	O
.	O
62	O

0	O
.	O
92	O

HDL	O
-	O
cholesterol	O

1	O
.	O
9	O
×	O
10	O
−	O
5	O

0	O
.	O
11	O

height	O

8	O
.	O
8	O
×	O
10	O
−	O
12	O

0	O
.	O
86	O

LDL	O
-	O
cholesterol	O

5	O
.	O
7	O
×	O
10	O
−	O
10	O

0	O
.	O
27	O

systolic	O
BP	O

0	O
.	O
11	O

0	O
.	O
21	O

total	O
cholesterol	O

6	O
.	O
6	O
×	O
10	O
−	O
9	O

0	O
.	O
21	O

triglycerides	O

4	O
.	O
1	O
×	O
10	O
−	O
8	O

2	O
.	O
9	O
×	O
10	O
−	O
5	O

Scores	O
based	O
on	O
the	O
genotypes	O
of	O
previously	O
reported	O
SNPs	O
were	O
used	O
to	O
test	O
for	O
association	O
with	O
effects	O
across	O
time	O
(	O
Score	O
)	O
or	O
time	O
-	O
dependent	O
effects	O
(	O
Score	O
×	O
Age	O
).	O

P	O
-	O
values	O
for	O
predictive	O
ability	O
of	O
previously	O
identified	O
SNPs	O
,	O
after	O
adjusting	O
for	O
first	O
measure	O
in	O
childhood	O
.	O

Trait	O

SNP	O

Alleles	O

BETA	O

SE	O

P	O

diastolic	O
BP	O

rs653178	O

T	O
/	O
C	O

−	O
1	O
.	O
2	O

0	O
.	O
5	O

0	O
.	O
025	O

glucose	O

rs560887	O

T	O
/	O
C	O

−	O
3	O
.	O
0	O

1	O
.	O
5	O

0	O
.	O
046	O

HDL	O
-	O
cholesterol	O

rs1532624	O

A	O
/	O
C	O

2	O
.	O
1	O

0	O
.	O
7	O

0	O
.	O
005	O

HDL	O
-	O
cholesterol	O

rs964184	O

G	O
/	O
C	O

−	O
2	O
.	O
8	O

1	O
.	O
1	O

0	O
.	O
015	O

HDL	O
-	O
cholesterol	O

rs157580	O

A	O
/	O
G	O

−	O
1	O
.	O
6	O

0	O
.	O
7	O

0	O
.	O
027	O

HDL	O
-	O
cholesterol	O

rs7395662	O

A	O
/	O
G	O

−	O
1	O
.	O
5	O

0	O
.	O
7	O

0	O
.	O
038	O

HDL	O
-	O
cholesterol	O

rs471364	O

T	O
/	O
C	O

2	O
.	O
2	O

1	O
.	O
1	O

0	O
.	O
049	O

height	O

rs185819	O

T	O
/	O
C	O

0	O
.	O
9	O

0	O
.	O
3	O

0	O
.	O
003	O

height	O

rs3748069	O

A	O
/	O
G	O

0	O
.	O
9	O

0	O
.	O
3	O

0	O
.	O
006	O

height	O

rs710841	O

C	O
/	O
T	O

−	O
0	O
.	O
8	O

0	O
.	O
3	O

0	O
.	O
013	O

height	O

rs4896582	O

A	O
/	O
G	O

−	O
0	O
.	O
8	O

0	O
.	O
3	O

0	O
.	O
013	O

height	O

rs967417	O

G	O
/	O
A	O

0	O
.	O
7	O

0	O
.	O
3	O

0	O
.	O
013	O

height	O

rs757608	O

G	O
/	O
A	O

−	O
0	O
.	O
7	O

0	O
.	O
3	O

0	O
.	O
031	O

height	O

rs3760318	O

A	O
/	O
G	O

−	O
0	O
.	O
6	O

0	O
.	O
3	O

0	O
.	O
032	O

height	O

rs16896068	O

A	O
/	O
G	O

−	O
0	O
.	O
8	O

0	O
.	O
4	O

0	O
.	O
037	O

height	O

rs6060373	O

A	O
/	O
G	O

−	O
0	O
.	O
6	O

0	O
.	O
3	O

0	O
.	O
048	O

LDL	O
-	O
cholesterol	O

rs12740374	O

G	O
/	O
T	O

6	O
.	O
3	O

2	O
.	O
4	O

0	O
.	O
009	O

LDL	O
-	O
cholesterol	O

rs12272004	O

A	O
/	O
C	O

−	O
8	O
.	O
7	O

4	O
.	O
1	O

0	O
.	O
034	O

systolic	O
BP	O

rs3184504	O

C	O
/	O
T	O

−	O
1	O
.	O
6	O

0	O
.	O
7	O

0	O
.	O
023	O

total	O
cholesterol	O

rs693	O

G	O
/	O
A	O

−	O
5	O
.	O
7	O

2	O
.	O
3	O

0	O
.	O
013	O

total	O
cholesterol	O

rs2304130	O

A	O
/	O
G	O

8	O
.	O
9	O

4	O
.	O
1	O

0	O
.	O
031	O

triglycerides	O

rs964184	O

G	O
/	O
C	O

51	O
.	O
7	O

10	O
.	O
7	O

1	O
.	O
9	O
×	O
10	O
−	O
6	O

triglycerides	O

rs780094	O

C	O
/	O
T	O

−	O
19	O
.	O
1	O

7	O
.	O
2	O

0	O
.	O
009	O

triglycerides	O

rs7819412	O

A	O
/	O
G	O

13	O
.	O
4	O

6	O
.	O
7	O

0	O
.	O
045	O

weight	O

rs7138803	O

G	O
/	O
A	O

−	O
2	O
.	O
2	O

1	O
.	O
0	O

0	O
.	O
037	O

Previously	O
associated	O
SNPs	O
were	O
tested	O
for	O
whether	O
they	O
were	O
associated	O
with	O
adult	O
level	O
traits	O
after	O
adjusting	O
for	O
the	O
trait	O
level	O
seen	O
in	O
childhood	O
.	O

Only	O
associations	O
at	O
P	O
<	O
0	O
.	O
05	O
are	O
shown	O
.	O

Discussion	O

We	O
identified	O
seven	O
associations	O
at	O
P	O
<	O
5	O
×	O
10	O
−	O
8	O
showing	O
either	O
time	O
-	O
averaged	O
or	O
time	O
-	O
dependent	O
effects	O
on	O
CVD	B-DS
risk	O
factors	O
in	O
the	O
BHS	O
,	O
two	O
of	O
which	O
have	O
been	O
previously	O
characterized	O
.	O

Of	O
all	O
associations	O
with	O
P	O
<	O
10	O
−	O
6	O
,	O
we	O
were	O
able	O
to	O
strongly	O
replicate	O
the	O
association	O
in	O
the	O
YF	O
with	O
HDL	O
-	O
cholesterol	O
at	O
CETP	B-GP
with	O
a	O
combined	O
P	O
=	O
9	O
.	O
7	O
×	O
10	O
−	O
24	O
,	O
and	O
LDL	O
-	O
cholesterol	O
at	O
APOE	B-GP
with	O
a	O
combined	O
P	O
=	O
8	O
.	O
7	O
×	O
10	O
−	O
19	O
.	O

Differences	O
that	O
exist	O
between	O
the	O
cohorts	O
,	O
such	O
as	O
birth	O
year	O
(	O
15	O
year	O
difference	O
),	O
and	O
environmental	O
differences	O
could	O
have	O
influenced	O
replication	O
of	O
the	O
remaining	O
SNPs	O
.	O

Larger	O
discovery	O
studies	O
will	O
also	O
have	O
better	O
resolution	O
and	O
power	O
to	O
accurately	O
estimate	O
longitudinal	O
effect	O
sizes	O
,	O
likely	O
allowing	O
for	O
more	O
robust	O
replication	O
.	O

We	O
evaluated	O
the	O
longitudinal	O
effects	O
of	O
markers	O
that	O
have	O
been	O
previously	O
identified	O
in	O
adult	O
GWA	O
studies	O
.	O

We	O
found	O
that	O
previously	O
identified	O
markers	O
showed	O
time	O
-	O
averaged	O
effects	O
consistent	O
with	O
their	O
reported	O
effect	O
size	O
.	O

This	O
argues	O
that	O
the	O
linear	O
mixed	O
model	O
is	O
an	O
effective	O
tool	O
for	O
modeling	O
time	O
-	O
averaged	O
effects	O
in	O
a	O
GWA	O
setting	O
and	O
that	O
adult	O
GWA	O
studies	O
may	O
be	O
capturing	O
variation	O
that	O
tends	O
to	O
have	O
consistent	O
effects	O
over	O
time	O
.	O

Using	O
a	O
scoring	O
approach	O
,	O
the	O
overall	O
signal	O
from	O
previously	O
identified	O
markers	O
tended	O
to	O
have	O
strong	O
associations	O
with	O
time	O
-	O
averaged	O
effects	O
,	O
but	O
except	O
in	O
the	O
case	O
of	O
triglycerides	O
,	O
did	O
not	O
show	O
time	O
-	O
dependent	O
effects	O
.	O

Previously	O
identified	O
markers	O
were	O
also	O
likely	O
to	O
be	O
associated	O
with	O
adult	O
trait	O
levels	O
above	O
and	O
beyond	O
childhood	O
levels	O
.	O

Although	O
we	O
primarily	O
describe	O
time	O
-	O
averaged	O
effects	O
for	O
previously	O
identified	O
markers	O
,	O
there	O
may	O
be	O
more	O
subtle	O
time	O
-	O
dependent	O
effects	O
that	O
larger	O
studies	O
will	O
be	O
better	O
able	O
to	O
capture	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
although	O
we	O
focused	O
on	O
analysis	O
of	O
linear	O
trends	O
over	O
time	O
,	O
a	O
linear	O
model	O
may	O
not	O
best	O
capture	O
these	O
trends	O
.	O

Other	O
approaches	O
could	O
be	O
explored	O
further	O
such	O
as	O
non	O
-	O
linear	O
models	O
when	O
there	O
is	O
an	O
a	O
priori	O
expectation	O
of	O
trait	O
trajectory	O
,	O
or	O
model	O
free	O
approaches	O
.	O

These	O
additional	O
models	O
could	O
lead	O
to	O
additional	O
variations	O
that	O
influence	O
trajectories	O
,	O
or	O
more	O
precise	O
estimations	O
of	O
effect	O
size	O
.	O

Longitudinal	O
studies	O
are	O
particularly	O
suited	O
to	O
capturing	O
effects	O
that	O
vary	O
over	O
time	O
.	O

Genetic	O
variation	O
that	O
shows	O
a	O
time	O
-	O
dependent	O
effect	O
may	O
help	O
predict	O
those	O
that	O
will	O
go	O
onto	O
develop	O
disease	O
before	O
they	O
show	O
symptomatic	O
traits	O
.	O

The	O
discovery	O
of	O
variants	O
associated	O
with	O
SNPxAGE	O
interaction	O
effects	O
could	O
thus	O
be	O
used	O
to	O
screen	O
young	O
individuals	O
who	O
are	O
pre	O
-	O
symptomatic	O
and	O
provide	O
the	O
opportunity	O
for	O
preventive	O
measures	O
decades	O
before	O
disease	O
onset	O
.	O

We	O
explored	O
how	O
well	O
the	O
markers	O
that	O
we	O
identified	O
predicted	O
adult	O
traits	O
after	O
correcting	O
for	O
childhood	O
traits	O
and	O
suggest	O
further	O
study	O
of	O
variants	O
with	O
SNPxAGE	O
effects	O
as	O
possibly	O
better	O
predictors	O
of	O
adult	O
trait	O
levels	O
above	O
and	O
beyond	O
childhood	O
levels	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
idea	O
that	O
longitudinal	O
studies	O
may	O
be	O
a	O
useful	O
tool	O
to	O
better	O
capture	O
time	O
-	O
dependent	O
variation	O
that	O
could	O
ultimately	O
be	O
better	O
predictive	O
of	O
future	O
outcomes	O
.	O

Materials	O
and	O
Methods	O

Ethics	O
statement	O

The	O
study	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
and	O
the	O
ethics	O
committee	O
of	O
each	O
institution	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
participant	O
in	O
accordance	O
with	O
institutional	O
requirements	O
and	O
the	O
Declaration	O
of	O
Helsinki	O
Principles	O
.	O

All	O
subjects	O
in	O
the	O
BHS	O
gave	O
informed	O
consent	O
at	O
each	O
examination	O
,	O
and	O
for	O
those	O
under	O
18	O
years	O
of	O
age	O
,	O
consent	O
of	O
a	O
parent	O
/	O
guardian	O
was	O
obtained	O
.	O

Study	O
protocols	O
were	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
the	O
Tulane	O
University	O
Health	O
Sciences	O
Center	O
.	O

The	O
Bogalusa	O
Heart	O
Study	O
(	O
BHS	O
)	O

Between	O
1973	O
and	O
2008	O
,	O
9	O
cross	O
-	O
sectional	O
surveys	O
of	O
children	O
aged	O
4	O
–	O
17	O
years	O
and	O
10	O
cross	O
-	O
sectional	O
surveys	O
of	O
adults	O
aged	O
18	O
–	O
48	O
years	O
(	O
Figure	O
S4	O
),	O
who	O
had	O
been	O
previously	O
examined	O
as	O
children	O
,	O
were	O
conducted	O
for	O
CVD	B-DS
risk	O
factor	O
examinations	O
in	O
Bogalusa	O
,	O
Louisiana	O
.	O

This	O
panel	O
design	O
of	O
repeated	O
cross	O
-	O
sectional	O
examinations	O
has	O
resulted	O
in	O
serial	O
observations	O
from	O
childhood	O
to	O
adulthood	O
.	O

By	O
linking	O
the	O
19	O
surveys	O
,	O
12	O
,	O
163	O
individuals	O
have	O
been	O
examined	O
,	O
with	O
37	O
,	O
317	O
observations	O
.	O

In	O
the	O
ongoing	O
Longitudinal	O
Aging	O
Study	O
funded	O
by	O
NIH	O
and	O
NIA	O
since	O
2000	O
,	O
there	O
are	O
1	O
,	O
202	O
subjects	O
who	O
have	O
been	O
examined	O
4	O
–	O
14	O
times	O
from	O
childhood	O
to	O
adulthood	O
and	O
have	O
DNA	O
available	O
for	O
GWA	O
genotyping	O
.	O

Based	O
on	O
the	O
analysis	O
of	O
identity	O
-	O
by	O
-	O
state	O
(	O
IBS	O
)	O
sharing	O
from	O
whole	O
genome	O
genotyping	O
data	O
,	O
we	O
focus	O
on	O
a	O
subset	O
of	O
525	O
genotyped	O
individuals	O
who	O
are	O
of	O
European	O
ancestry	O
and	O
unrelated	O
(	O
229	O
male	O
,	O
296	O
female	O
).	O

The	O
average	O
number	O
of	O
measurements	O
per	O
individual	O
is	O
8	O
(	O
range	O
4	O
–	O
13	O
).	O

The	O
Cardiovascular	O
Risk	O
in	O
Young	O
Finns	O
Study	O
(	O
YF	O
)	O

The	O
YF	O
cohort	O
is	O
a	O
Finnish	O
longitudinal	O
population	O
study	O
sample	O
on	O
the	O
evolution	O
of	O
cardiovascular	O
risk	O
factors	O
from	O
childhood	O
to	O
adulthood	O
[	O
21	O
].	O

The	O
first	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
in	O
1980	O
in	O
five	O
centers	O
and	O
included	O
3	O
,	O
596	O
participants	O
in	O
the	O
age	O
groups	O
of	O
3	O
,	O
6	O
,	O
9	O
,	O
12	O
,	O
15	O
,	O
and	O
18	O
,	O
who	O
were	O
randomly	O
chosen	O
from	O
the	O
national	O
population	O
register	O
.	O

After	O
baseline	O
in	O
1980	O
these	O
subjects	O
have	O
been	O
re	O
-	O
examined	O
in	O
1983	O
and	O
1986	O
as	O
young	O
individuals	O
,	O
and	O
in	O
2001	O
and	O
2007	O
as	O
older	O
individuals	O
.	O

Genotype	O
data	O
for	O
the	O
present	O
analysis	O
(	O
DNA	O
collected	O
in	O
1980	O
,	O
2001	O
and	O
2007	O
)	O
was	O
available	O
for	O
2	O
,	O
442	O
individuals	O
.	O

In	O
the	O
latest	O
follow	O
-	O
up	O
in	O
2001	O
,	O
a	O
total	O
of	O
2	O
,	O
283	O
participants	O
(	O
of	O
which	O
DNA	O
is	O
available	O
from	O
2	O
,	O
265	O
participants	O
)	O
were	O
examined	O
for	O
numerous	O
study	O
variables	O
,	O
including	O
serum	O
lipoproteins	O
,	O
glucose	O
,	O
insulin	B-GP
,	O
obesity	B-DS
indices	O
,	O
blood	O
pressure	O
,	O
life	O
-	O
style	O
factors	O
,	O
smoking	O
status	O
,	O
alcohol	O
use	O
and	O
general	O
health	O
status	O
.	O

Genotyping	O
&	O
QC	O

BHS	O
genotyping	O

We	O
genotyped	O
1	O
,	O
202	O
BHS	O
samples	O
using	O
the	O
Illumina	O
Human610	O
Genotyping	O
BeadChip	O
[	O
22	O
],	O
and	O
HumanCVD	O
BeadChip	O
[	O
11	O
].	O

Genotypes	O
were	O
called	O
using	O
a	O
clustering	O
algorithm	O
in	O
Illumina	O
'	O
s	O
BeadStudio	O
software	O
.	O

Three	O
samples	O
on	O
the	O
Human610	O
BeadChip	O
gave	O
poor	O
results	O
(	O
call	O
rates	O
<	O
99	O
%)	O
and	O
were	O
discarded	O
from	O
the	O
study	O
.	O

In	O
addition	O
,	O
3	O
samples	O
had	O
a	O
different	O
estimated	O
gender	O
from	O
genotype	O
data	O
versus	O
gender	O
provided	O
with	O
the	O
phenotype	O
data	O
and	O
were	O
also	O
discarded	O
.	O

SNPs	O
with	O
call	O
rates	O
<	O
90	O
%	O
were	O
discarded	O
,	O
and	O
SNPs	O
with	O
call	O
rates	O
between	O
90	O
–	O
95	O
%	O
or	O
cluster	O
separation	O
score	O
<	O
0	O
.	O
3	O
were	O
manually	O
inspected	O
and	O
cluster	O
positions	O
were	O
edited	O
if	O
needed	O
.	O

We	O
removed	O
approximately	O
30	O
,	O
000	O
SNP	O
loci	O
(	O
4	O
.	O
9	O
%)	O
due	O
to	O
poor	O
performance	O
.	O

The	O
final	O
average	O
sample	O
call	O
rate	O
was	O
99	O
.	O
95	O
%	O
for	O
the	O
Human610	O
BeadChip	O
,	O
and	O
99	O
.	O
32	O
%	O
for	O
the	O
CVD	B-DS
BeadChip	O
.	O

We	O
assessed	O
reproducibility	O
by	O
genotyping	O
29	O
samples	O
in	O
duplicate	O
(	O
18	O
known	O
replicates	O
,	O
11	O
blind	O
replicates	O
),	O
and	O
observed	O
>	O
99	O
.	O
99	O
%	O
identical	O
genotype	O
calls	O
on	O
both	O
BeadChips	O
.	O

Finally	O
we	O
observed	O
99	O
.	O
98	O
%	O
genotype	O
concordance	O
in	O
12	O
,	O
581	O
overlapping	O
SNPs	O
between	O
the	O
610	O
and	O
CVD	B-DS
BeadChips	O
.	O

A	O
final	O
list	O
of	O
545	O
,	O
821	O
unique	O
SNPs	O
passed	O
QC	O
and	O
allele	O
frequency	O
filters	O
.	O

YF	O
study	O
genotyping	O

For	O
replication	O
,	O
we	O
had	O
genome	O
-	O
wide	O
SNP	O
data	O
from	O
a	O
custom	O
Illumina	O
BeadChip	O
containing	O
670	O
,	O
000	O
SNPs	O
and	O
CNV	O
probes	O
from	O
2	O
,	O
442	O
YF	O
participants	O
(	O
1	O
,	O
123	O
males	O
,	O
1	O
,	O
319	O
females	O
).	O

The	O
custom	O
content	O
on	O
the	O
custom	O
670K	O
array	O
replaced	O
some	O
poor	O
performing	O
SNPs	O
on	O
the	O
Human610	O
BeadChip	O
and	O
added	O
more	O
CNV	O
content	O
,	O
and	O
includes	O
546	O
,	O
677	O
SNPs	O
passing	O
QC	O
from	O
594	O
,	O
210	O
SNPs	O
on	O
the	O
chip	O
.	O

The	O
custom	O
670K	O
chip	O
shares	O
562	O
,	O
643	O
SNPs	O
in	O
common	O
with	O
the	O
Illumina	O
Human610	O
BeadChip	O
.	O

Genotypes	O
were	O
called	O
using	O
Illumina	O
'	O
s	O
clustering	O
algorithm	O
[	O
23	O
].	O

A	O
total	O
of	O
2	O
,	O
556	O
samples	O
were	O
genotyped	O
.	O

After	O
initial	O
clustering	O
,	O
we	O
removed	O
2	O
subjects	O
for	O
poor	O
call	O
rates	O
(	O
CR	O
<	O
0	O
.	O
90	O
),	O
and	O
54	O
samples	O
failed	O
subsequent	O
QC	O
(	O
i	O
.	O
e	O
.,	O
duplicated	O
samples	O
,	O
heterozygosity	O
,	O
low	O
call	O
rate	O
,	O
or	O
custom	O
SNP	O
fingerprint	O
genotype	O
discrepancy	O
).	O

The	O
following	O
filters	O
were	O
applied	O
to	O
the	O
remaining	O
data	O
:	O
MAF	O
0	O
.	O
01	O
,	O
GENO	O
0	O
.	O
05	O
,	O
MIND	O
0	O
.	O
05	O
,	O
and	O
HWE	O
1	O
×	O
10	O
−	O
6	O
.	O

Three	O
of	O
2	O
,	O
500	O
individuals	O
were	O
removed	O
for	O
low	O
genotyping	O
(	O
MIND	O
>	O
0	O
.	O
05	O
),	O
11	O
,	O
766	O
markers	O
were	O
excluded	O
based	O
on	O
HWE	O
test	O
(	O
P	O
≤	O
1	O
×	O
10	O
−	O
6	O
),	O
7	O
,	O
746	O
SNPs	O
failed	O
missingness	O
test	O
(	O
GENO	O
>	O
0	O
.	O
05	O
),	O
34	O
,	O
596	O
SNPs	O
failed	O
frequency	O
test	O
(	O
MAF	O
<	O
0	O
.	O
01	O
)	O
and	O
one	O
individual	O
failed	O
gender	O
check	O
.	O

A	O
final	O
list	O
of	O
546	O
,	O
677	O
SNPs	O
passed	O
QC	O
and	O
allele	O
frequency	O
filters	O
.	O

Assessing	O
cryptic	O
relatedness	O

Bogalusa	O
participants	O
with	O
genotype	O
data	O
were	O
filtered	O
for	O
relatedness	O
.	O

Whole	O
-	O
genome	O
genotype	O
data	O
was	O
used	O
to	O
calculate	O
identity	O
-	O
by	O
-	O
descent	O
(	O
PI_HAT	O
)	O
values	O
in	O
PLINK	O
[	O
24	O
].	O

Individuals	O
were	O
then	O
removed	O
such	O
that	O
no	O
pair	O
of	O
individuals	O
retained	O
a	O
PI_HAT	O
value	O
greater	O
than	O
0	O
.	O
10	O
.	O

PI_HAT	O
values	O
were	O
consistent	O
with	O
known	O
sibling	O
and	O
half	O
-	O
sibling	O
relationships	O
.	O

The	O
final	O
list	O
consisted	O
of	O
525	O
BHS	O
individuals	O
.	O

In	O
the	O
YF	O
data	O
,	O
there	O
were	O
546	O
,	O
770	O
SNPs	O
and	O
2	O
,	O
496	O
individuals	O
which	O
were	O
utilized	O
to	O
generate	O
an	O
identity	O
-	O
by	O
-	O
descent	O
(	O
IBD	O
)	O
matrix	O
file	O
in	O
PLINK	O
[	O
24	O
].	O

There	O
were	O
51	O
pairs	O
of	O
individuals	O
with	O
pi	O
-	O
hat	O
greater	O
than	O
0	O
.	O
2	O
thus	O
these	O
individuals	O
removed	O
due	O
to	O
possible	O
relatedness	O
.	O

One	O
of	O
the	O
pair	O
was	O
removed	O
using	O
greater	O
missingness	O
as	O
criteria	O
.	O

The	O
final	O
list	O
consisted	O
of	O
2	O
,	O
442	O
YF	O
subjects	O
.	O

Imputation	O

We	O
imputed	O
genotypes	O
in	O
genotyped	O
BHS	O
individuals	O
for	O
all	O
HapMap	O
(	O
phase	O
II	O
,	O
release	O
22	O
)	O
SNPs	O
using	O
the	O
program	O
MACH	O
[	O
12	O
].	O

The	O
best	O
estimate	O
of	O
the	O
quantitative	O
allele	O
dosage	O
was	O
used	O
as	O
the	O
predictor	O
in	O
association	O
tests	O
.	O

The	O
CEU	O
HapMap	O
phased	O
haplotypes	O
were	O
used	O
as	O
a	O
reference	O
(	O
N	O
=	O
60	O
unrelated	O
individuals	O
).	O

This	O
resulted	O
in	O
overall	O
allelic	O
error	O
rates	O
of	O
1	O
.	O
6	O
%.	O

SNPs	O
were	O
filtered	O
for	O
minor	O
allele	O
frequency	O
(<	O
5	O
%)	O
and	O
r2	O
with	O
respect	O
to	O
genotyped	O
SNPs	O
(<	O
0	O
.	O
30	O
),	O
resulting	O
in	O
genotype	O
data	O
in	O
a	O
total	O
of	O
2	O
,	O
173	O
,	O
391	O
SNPs	O
.	O

Imputation	O
was	O
performed	O
in	O
the	O
YF	O
samples	O
using	O
MACH	O
with	O
the	O
HapMap	O
release	O
22	O
CEU	O
haplotypes	O
as	O
reference	O
.	O

Prediction	O
ability	O

Previously	O
identified	O
markers	O
were	O
obtained	O
through	O
the	O
NHGRI	O
database	O
[	O
25	O
]	O
(	O
accessed	O
5	O
/	O
20	O
/	O
09	O
).	O

Marker	O
associations	O
,	O
alleles	O
,	O
and	O
allele	O
frequencies	O
were	O
verified	O
with	O
those	O
reported	O
in	O
the	O
original	O
papers	O
and	O
corrected	O
if	O
required	O
.	O

Markers	O
were	O
used	O
if	O
the	O
alleles	O
at	O
the	O
locus	O
provided	O
unambiguous	O
orientation	O
or	O
if	O
the	O
allele	O
frequencies	O
were	O
different	O
enough	O
between	O
A	O
/	O
T	O
and	O
C	O
/	O
G	O
SNPs	O
to	O
distinguish	O
which	O
allele	O
was	O
the	O
associated	O
allele	O
.	O

We	O
thus	O
excluded	O
any	O
A	O
/	O
T	O
or	O
C	O
/	O
G	O
SNPs	O
with	O
a	O
minor	O
allele	O
frequency	O
>	O
0	O
.	O
4	O
and	O
required	O
that	O
the	O
allele	O
frequency	O
in	O
the	O
previously	O
reported	O
study	O
be	O
within	O
10	O
%	O
of	O
the	O
allele	O
frequency	O
in	O
the	O
BHS	O
.	O

We	O
excluded	O
studies	O
of	O
non	O
-	O
European	O
Ancestry	O
origin	O
.	O

One	O
SNP	O
per	O
cytogenic	O
region	O
was	O
used	O
for	O
each	O
phenotype	O
:	O
the	O
SNP	O
with	O
the	O
smallest	O
previously	O
reported	O
p	O
-	O
value	O
was	O
used	O
.	O

Effect	O
size	O
was	O
translated	O
to	O
percent	O
standard	O
deviation	O
.	O

If	O
the	O
effect	O
size	O
was	O
reported	O
in	O
an	O
absolute	O
measure	O
(	O
e	O
.	O
g	O
.	O
cm	O
for	O
height	O
),	O
then	O
the	O
standard	O
deviation	O
from	O
the	O
BHS	O
study	O
was	O
used	O
.	O

Standard	O
deviation	O
was	O
calculated	O
from	O
the	O
standard	O
error	O
of	O
the	O
SNP	O
association	O
reported	O
in	O
the	O
linear	O
mixed	O
model	O
.	O

For	O
glucose	O
,	O
cholesterol	O
,	O
and	O
triglycerides	O
measures	O
,	O
units	O
were	O
converted	O
to	O
mg	O
/	O
dl	O
before	O
converting	O
to	O
%	O
SD	O
.	O

A	O
risk	O
value	O
was	O
calculated	O
for	O
each	O
individual	O
based	O
on	O
the	O
imputed	O
genotype	O
and	O
previously	O
reported	O
effect	O
size	O
,	O
converted	O
to	O
%	O
SD	O
.	O

The	O
%	O
SD	O
was	O
multiplied	O
by	O
the	O
allelic	O
dosage	O
for	O
each	O
SNP	O
and	O
summed	O
over	O
all	O
the	O
associated	O
SNPs	O
for	O
each	O
phenotype	O
.	O

The	O
resulting	O
risk	O
value	O
was	O
then	O
used	O
as	O
a	O
predictor	O
for	O
the	O
BHS	O
individuals	O
.	O

Genome	O
-	O
wide	O
association	O

GWA	O
was	O
performed	O
using	O
linear	O
mixed	O
model	O
regression	O
with	O
fixed	O
covariates	O
of	O
age	O
and	O
sex	O
,	O
random	O
slope	O
,	O
and	O
random	O
intercept	O
.	O

Genotypes	O
were	O
coded	O
as	O
0	O
,	O
1	O
,	O
or	O
2	O
when	O
the	O
SNP	O
was	O
genotyped	O
and	O
by	O
dosage	O
(	O
scale	O
0	O
–	O
2	O
)	O
when	O
imputed	O
.	O

Analysis	O
was	O
performed	O
within	O
the	O
nlme	O
package	O
in	O
R	O
[	O
13	O
].	O

Covariance	O
structures	O
were	O
determined	O
by	O
testing	O
all	O
spatial	O
covariance	O
structures	O
(	O
exponential	O
,	O
Gaussian	O
,	O
linear	O
,	O
rational	O
quadradics	O
,	O
and	O
spherical	O
)	O
with	O
covariates	O
and	O
a	O
sample	O
of	O
SNPs	O
,	O
and	O
picking	O
the	O
structure	O
that	O
best	O
fit	O
the	O
data	O
as	O
measured	O
by	O
the	O
lowest	O
AIC	O
(	O
Akaike	O
Information	O
Criteria	O
)	O
value	O
.	O

SNP	O
and	O
SNPxAGE	O
interaction	O
effects	O
were	O
estimated	O
separately	O
.	O

Although	O
the	O
default	O
nlme	O
optimizer	O
tended	O
to	O
have	O
difficulty	O
converging	O
,	O
we	O
obtained	O
good	O
results	O
by	O
using	O
the	O
optim	O
optimizer	O
on	O
data	O
where	O
all	O
missing	O
data	O
was	O
removed	O
.	O

The	O
number	O
of	O
SNPs	O
that	O
converged	O
and	O
for	O
which	O
we	O
obtained	O
results	O
is	O
listed	O
in	O
Table	O
S1	O
.	O

Analyses	O
were	O
performed	O
on	O
a	O
compute	O
cluster	O
with	O
600	O
,	O
000	O
tests	O
taking	O
∼	O
3	O
hrs	O
on	O
64	O
processors	O
.	O

Filtering	O
for	O
genomic	O
inflation	O

If	O
genomic	O
inflation	O
factors	O
were	O
inflated	O
or	O
deflated	O
,	O
we	O
reran	O
the	O
GWA	O
using	O
the	O
first	O
four	O
MDS	O
components	O
as	O
covariates	O
.	O

If	O
the	O
inflation	O
factor	O
was	O
still	O
less	O
than	O
0	O
.	O
90	O
or	O
greater	O
than	O
1	O
.	O
05	O
,	O
we	O
removed	O
the	O
analysis	O
.	O

In	O
addition	O
,	O
we	O
filtered	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
SNP	O
,	O
BMI	O
SNPxAGE	O
,	O
and	O
weight	O
SNP	O
analyses	O
completely	O
from	O
the	O
analysis	O
due	O
to	O
a	O
combination	O
of	O
consistently	O
inflated	O
or	O
deflated	O
genomic	O
inflation	O
factors	O
or	O
a	O
long	O
list	O
of	O
highly	O
associated	O
SNPs	O
.	O

Power	O

Power	O
was	O
calculated	O
using	O
G	O
*	O
Power	O
3	O
[	O
26	O
].	O
We	O
used	O
the	O
MANOVA	O
repeated	O
measures	O
module	O
with	O
8	O
repeated	O
measures	O
with	O
a	O
correlation	O
of	O
0	O
.	O
5	O
between	O
them	O
,	O
similar	O
to	O
the	O
correlations	O
seen	O
in	O
this	O
study	O
.	O

We	O
estimated	O
power	O
for	O
between	O
-	O
factor	O
and	O
between	O
-	O
within	O
interaction	O
effects	O
.	O

Effect	O
size	O
(	O
f	O
)	O
was	O
calculated	O
asand	O
R2	O
was	O
calculated	O
from	O
the	O
allele	O
frequencies	O
as	O
reported	O
in	O
the	O
original	O
associations	O
(	O
p	O
and	O
q	O
)	O
and	O
the	O
effect	O
size	O
in	O
terms	O
of	O
%	O
SD	O
[	O
27	O
].	O

Supporting	O
Information	O

Regional	O
plots	O
of	O
top	O
SNP	O
and	O
SNPxAGE	O
associations	O
.	O

Regions	O
are	O
ordered	O
by	O
phenotype	O
and	O
significance	O
as	O
in	O
Table	O
1	O
and	O
2	O
.	O

SNPs	O
are	O
indicated	O
by	O
triangle	O
(	O
directly	O
genotyped	O
)	O
or	O
square	O
(	O
imputed	O
),	O
and	O
colored	O
according	O
to	O
LD	O
(	O
r2	O
)	O
with	O
the	O
top	O
SNP	O
with	O
increasing	O
shades	O
of	O
red	O
indicating	O
stronger	O
LD	O
.	O

Blue	O
lines	O
indicate	O
recombination	O
hotspots	O
and	O
refSeq	O
genes	O
are	O
indicated	O
.	O

(	O
8	O
.	O
26	O
MB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Manhattan	O
Plots	O
of	O
GWAS	O
results	O
for	O
each	O
trait	O
.	O

Manhattan	O
plots	O
are	O
shown	O
for	O
each	O
SNP	O
and	O
SNPxAGE	O
GWAS	O
.	O

Each	O
point	O
corresponds	O
to	O
an	O
association	O
with	O
triangles	O
indicating	O
directly	O
genotyped	O
data	O
and	O
circles	O
indicating	O
imputed	O
data	O
.	O

A	O
horizontal	O
line	O
is	O
plotted	O
at	O
P	O
=	O
10	O
−	O
6	O
and	O
SNPs	O
above	O
this	O
point	O
are	O
outlined	O
in	O
pink	O
.	O

These	O
SNPs	O
occur	O
in	O
Tables	O
1	O
,	O
2	O
,	O
and	O
3	O
.	O

Chromosomes	O
are	O
plotted	O
in	O
alternating	O
blue	O
and	O
grey	O
.	O
P	O
-	O
values	O
greater	O
than	O
0	O
.	O
001	O
are	O
not	O
plotted	O
.	O

(	O
8	O
.	O
19	O
MB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Longitudinal	O
profiles	O
of	O
cumulative	O
score	O
from	O
previously	O
identified	O
SNPs	O
.	O

Individuals	O
were	O
scored	O
based	O
on	O
the	O
effect	O
size	O
of	O
each	O
previously	O
identified	O
marker	O
as	O
in	O
Figure	O
1B	O
.	O

Individuals	O
are	O
grouped	O
and	O
color	O
-	O
coded	O
based	O
on	O
the	O
decile	O
of	O
their	O
score	O
.	O

Linear	O
lines	O
were	O
calculated	O
using	O
linear	O
regression	O
with	O
all	O
points	O
from	O
all	O
individuals	O
in	O
a	O
given	O
decile	O
.	O

(	O
1	O
.	O
26	O
MB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Age	O
at	O
measurement	O
in	O
the	O
BHS	O
.	O

All	O
exam	O
dates	O
that	O
were	O
included	O
in	O
the	O
study	O
are	O
plotted	O
as	O
a	O
function	O
of	O
the	O
age	O
of	O
participant	O
at	O
the	O
exam	O
date	O
.	O

Individuals	O
had	O
between	O
4	O
–	O
13	O
measurements	O
.	O

A	O
single	O
individual	O
is	O
highlighted	O
in	O
red	O
.	O

(	O
0	O
.	O
27	O
MB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Number	O
of	O
SNPs	O
that	O
successfully	O
converged	O
and	O
produced	O
association	O
statistics	O
.	O

(	O
0	O
.	O
06	O
MB	O
XLSX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

